| EOS-AX0963 | BMS-345541(free base) | 445430-58-0 | C14H17N5 | 255.32 | |
| EOS-AX0964 | BMS-509744 | 439575-02-7 | C32H41N5O4S2 | 623.83 | CC1=C(SC(S2)=CN=C2NC(C3=CC=C(CNC(C(C)(C)C)C)C=C3)=O)C=C(C(N4CCN(C(C)=O)CC4)=O)C(OC)=C1 |
| EOS-AX0965 | BMS-564929 | 627530-84-1 | C14H12ClN3O3 | 305.72 | CC1=C(C=CC(=C1Cl)C#N)N2C(=O)C3C(CCN3C2=O)O |
| EOS-AX0966 | BMS-599626 Hydrochloride | 873837-23-1 | C27H28ClFN8O3 | 567.01 | CC1=C2C(=NC=NN2C=C1NC(=O)OCC3COCCN3)NC4=CC5=C(C=C4)N(N=C5)CC6=CC(=CC=C6)F.Cl |
| EOS-AX0967 | BMS-626529 | 701213-36-7 | C24H23N7O4 | 473.48 | CC1=NN(C=N1)C2=NC=C(C3=C2NC=C3C(=O)C(=O)N4CCN(CC4)C(=O)C5=CC=CC=C5)OC |
| EOS-AX0968 | BMS-663068 | 864953-29-7 | C25H26N7O8P | 583.49 | CC1=NN(C2=NC=C(OC)C3=C2N(COP(O)(O)=O)C=C3C(C(N4CCN(C(C5=CC=CC=C5)=O)CC4)=O)=O)C=N1 |
| EOS-AX0969 | BMS-663068 Tris | 864953-39-9 | C29H37N8O11P | 704.62 | CC1=NN(C2=NC=C(OC)C3=C2N(COP(O)([O-])=O)C=C3C(C(N4CCN(C(C5=CC=CC=C5)=O)CC4)=O)=O)C=N1.OCC(CO)([NH3+])CO |
| EOS-AX0970 | BMS-690514 | 859853-30-8 | C19H24N6O2 | 368.44 | COC1=CC=CC(=C1)NC2=NC=NN3C2=C(C=C3)CN4CCC(C(C4)O)N |
| EOS-AX0971 | BMS-790052 dihydrochloride | 1009119-65-6 | C40H52Cl2N8O6 | 811.8 | CC(C)[C@H](NC(OC)=O)C(N1[C@H](C2=NC=C(C3=CC=C(C4=CC=C(C5=CN=C([C@@H]6CCCN6C([C@@H](NC(OC)=O)C(C)C)=O)N5)C=C4)C=C3)N2)CCC1)=O.Cl.Cl |
| EOS-AX0972 | BMS-833923 | 1059734-66-5 | C30H27N5O | 473.57 | CC1=C(C=C(C=C1)CNC)NC(=O)C2=CC=C(C=C2)NC3=NC4=CC=CC=C4C(=N3)C5=CC=CC=C5 |
| EOS-AX0973 | BMS-927711 | 1289023-67-1 | C28H28F2N6O3 | 534.56 | FC1=CC=CC(C2C(N)C(C=CC=N3)=C3C(OC(N4CCC(N5C6=C(N=CC=C6)NC5=O)CC4)=O)CC2)=C1F |
| EOS-AX0974 | BMX-IN-1 | 1431525-23-3 | C29H24N4O4S | 524.59 | CC1=C(C=C(C=C1)N2C(=O)C=CC3=CN=C4C=CC(=CC4=C32)C5=CC=C(C=C5)NS(=O)(=O)C)NC(=O)C=C |
| EOS-AX0975 | Boceprevir | 394730-60-0 | C27H45N5O5 | 519.68 | CC1(C2C1C(N(C2)C(=O)C(C(C)(C)C)NC(=O)NC(C)(C)C)C(=O)NC(CC3CCC3)C(=O)C(=O)N)C |
| EOS-AX0976 | Boldenone Undecylenate | 13103-34-9 | C30H44O3 | 452.67 | |
| EOS-AX0977 | BRAF inhibitor | 918505-61-0 | C22H18F2N4O3S | 456.47 | CC(C)S(=O)(=O)NC1=C(C(=C(C=C1)F)C(=O)C2=CNC3=NC=C(C=C23)C4=CN=CC=C4)F |
| EOS-AX0978 | B-Raf inhibitor | 1315330-11-0 | C29H31F3N6O2 | 552.59 | CCN1CCN(CC1)CC2=C(C=C(C=C2)NC(=O)C3=CC(=C(C=C3)C)OC4=NC=NC5=C4C=C(N5)C)C(F)(F)F |
| EOS-AX0979 | Brassinolide | 72962-43-7 | C28H48O6 | 480.68 | CC(C)[C@H](C)[C@@H](O)[C@H](O)[C@@H](C)[C@@]1([H])CC[C@@]2([H])[C@]3([H])COC([C@@]4([H])C[C@H](O)[C@H](O)C[C@]4(C)[C@@]3([H])CC[C@@]21C)=O |
| EOS-AX0980 | BS-181 | 1092443-52-1 | C22H32N6 | 380.53 | CC(C)C1=C2N=C(C=C(N2N=C1)NCC3=CC=CC=C3)NCCCCCCN |
| EOS-AX0981 | CAL-130 | 1431697-74-3 | C23H22N8O | 426.47 | CC1=C2C(N=C(C(NC3=NC(N)=NC4=C3NC=N4)C)N(C5=CC=CC=C5C)C2=O)=CC=C1 |
| EOS-AX0982 | CAL-130 Hydrochloride | 1431697-78-7 | C23H23ClN8O | 462.93 | O=C1N(C2=CC=CC=C2C)C([C@@H](C)NC3=NC(N)=NC4=C3NC=N4)=NC5=CC=CC(C)=C15.Cl |
| EOS-AX0983 | CAL-130 Racemate | 474012-90-3 | C23H22N8O | 426.47 | CC1=C2C(=CC=C1)N=C(N(C2=O)C3=CC=CC=C3C)C(C)NC4=NC(=NC5=C4NC=N5)N |
| EOS-AX0984 | Calcifediol monohydrate | 63283-36-3 | C27H46O3 | 418.65 | CC(CCCC(C)(C)O)C1CCC2C1(CCCC2=CC=C3CC(CCC3=C)O)C.O |
| EOS-AX0985 | Calcipotriol | 112965-21-6 | C27H40O3 | 412.62 | CC(C=CC(C1CC1)O)C2CCC3C2(CCCC3=CC=C4CC(CC(C4=C)O)O)C |
| EOS-AX0986 | Calcipotriol monohydrate | 147657-22-5 | C27H42O4 | 430.62 | CC(C=CC(C1CC1)O)C2CCC3C2(CCCC3=CC=C4CC(CC(C4=C)O)O)C.O |
| EOS-AX0987 | Calcitetrol | 72203-93-1 | C27H44O4 | 432.64 | CC(CCC(C(C)(C)O)O)C1CCC2C1(CCCC2=CC=C3CC(CC(C3=C)O)O)C |
| EOS-AX0988 | Calcitriol D6 | 78782-99-7 | C27H44O3 | 422.67 | CC(CCCC(C)(C)O)C1CCC2C1(CCCC2=CC=C3CC(CC(C3=C)O)O)C |
| EOS-AX0989 | Calcium-Sensing Receptor Antagonists I | 478963-79-0 | C23H24N2O2 | 360.46 | CC(C)C1=CC=C(C=C1)C2=NC(=O)N(C3=C2C=C(C=C3)OCC#C)C(C)C |
| EOS-AX0990 | Canertinib dihydrochloride | 289499-45-2 | C24H27Cl3FN5O3 | 558.87 | C=CC(=O)NC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4.Cl.Cl |
| EOS-AX0991 | Capadenoson | 544417-40-5 | C25H18ClN5O2S2 | 520.03 | C1=CC(=CC=C1C2=C(C(=NC(=C2C#N)SCC3=CSC(=N3)C4=CC=C(C=C4)Cl)N)C#N)OCCO |
| EOS-AX0992 | Capsaicin | 404-86-4 | C18H27NO3 | 305.41 | CC(C)C=CCCCCC(=O)NCC1=CC(=C(C=C1)O)OC |
| EOS-AX0993 | Capsazepine | 138977-28-3 | C19H21ClN2O2S | 376.9 | C1CC2=CC(=C(C=C2CN(C1)C(=S)NCCC3=CC=C(C=C3)Cl)O)O |
| EOS-AX0994 | Captisol | 182410-00-0 | C50H84Na2O41S2 | 1451.29 | |
| EOS-AX0995 | Carboxypeptidase G2 (CPG2) Inhibitor | 192203-60-4 | C13H15NO6S | 313.33 | COC1=CC=C(C=C1)SC(=O)NC(CCC(=O)O)C(=O)O |
| EOS-AX0996 | Cariprazine | 839712-12-8 | C21H32Cl2N4O | 427.41 | CN(C)C(=O)NC1CCC(CC1)CCN2CCN(CC2)C3=C(C(=CC=C3)Cl)Cl |
| EOS-AX0997 | Cariprazine hydrochloride | 1083076-69-0 | C21H33Cl3N4O | 463.87 | CN(C)C(=O)NC1CCC(CC1)CCN2CCN(CC2)C3=C(C(=CC=C3)Cl)Cl.Cl |
| EOS-AX0998 | Cathepsin S inhibitor | 1373215-15-6 | C25H29FN4O5 | 484.52 | CNC(=O)OC1COC2=C(C1NC(=O)C3=CC=C(C=C3)F)C=C(C=C2)N4CCN(CC4)C5COC5 |
| EOS-AX0999 | CB 300919 | 289715-28-2 | C32H34ClN7O2 | 584.11 | CN1CCN(CC1)CC2=NC3=CC(=C(C=C3C(=O)N2C)CN(CC#C)C4=CC=C(C=C4)C(=O)NCC5=CN=CC=C5)Cl |
| EOS-AX1000 | CB30865 | 206275-15-2 | C26H22BrN5O2 | 516.39 | CC1=NC(=O)C2=CC(=C(C=C2N1)Br)CN(CC#C)C3=CC=C(C=C3)C(=O)NCC4=CN=CC=C4 |
| EOS-AX1001 | CC-401 hydrochloride | 1438391-30-0 | C22H25ClN6O | 424.93 | C1CCN(CC1)CCOC2=CC=CC(=C2)C3=NNC4=C3C=C(C=C4)C5=NC=NN5.Cl |
| EOS-AX1002 | CC-930 | 899805-25-5 | C21H23F3N6O2 | 448.44 | C1CC(CCC1NC2=NC=C3C(=N2)N(C(=N3)NC4=C(C=C(C=C4F)F)F)C5CCOC5)O |
| EOS-AX1003 | CCG-63802 | 620112-78-9 | C26H18N4O2S | 450.52 | CC1=CC(=CC=C1)OC2=C(C(=O)N3C=CC=C(C3=N2)C)C=C(C#N)C4=NC5=CC=CC=C5S4 |
| EOS-AX1004 | CCG-63808 | 620113-73-7 | C25H15FN4O2S | 454.49 | CC1=CC=CN2C1=NC(=C(C2=O)C=C(C#N)C3=NC4=CC=CC=C4S3)OC5=CC=C(C=C5)F |
| EOS-AX1005 | CCT241533 | 1262849-73-9 | C23H27FN4O4 | 442.48 | CC(C1CNCC1NC2=N/C(NC3=CC(OC)=C(OC)C=C32)=C4C=C(F)C=CC\4=O)(O)C |
| EOS-AX1006 | CCT241533 hydrochloride | 1431697-96-9 | C23H28ClFN4O4 | 478.94 | CC(C)(C1CNCC1NC2=NC(=C3C=C(C=CC3=O)F)NC4=CC(=C(C=C42)OC)OC)O.Cl |
| EOS-AX1007 | CDK inhibitor II | 1269815-17-9 | C18H19ClFN3O2 | 363.82 | COC1=C(C=C(C=C1)F)C2=CC(=NC=C2Cl)NC(=O)C3CCCNC3 |
| EOS-AX1008 | CDK9 inhibitor | 1415559-43-1 | C26H21N5O4S | 499.54 | CC1=C(C=C(C=C1)NC2=NC=NC(=C2)C3=CC(=CC=C3)N4C(=O)C5=CC=CC=C5C4=O)NS(=O)(=O)C |
| EOS-AX1009 | CDK9 inhibitor 2 | 1263369-28-3 | C23H25ClFN5 | 425.93 | C1CC(CCC1N)NC2=NC=C(C(=C2)C3=NC(=CC=C3)NCC4=CC(=CC=C4)F)Cl |
| EOS-AX1010 | Cebranopadol | 863513-91-1 | C24H27FN2O | 378.48 | CN(C)C1(CCC2(CC1)C3=C(CCO2)C4=C(N3)C=CC(=C4)F)C5=CC=CC=C5 |
| EOS-AX1011 | CEP-32496 hydrochloride | 1227678-26-3 | C24H23ClF3N5O5 | 553.92 | CC(C)(C1=CC(=NO1)NC(=O)NC2=CC(=CC=C2)OC3=NC=NC4=CC(=C(C=C43)OC)OC)C(F)(F)F.Cl |
| EOS-AX1012 | Cetirizine | 83881-51-0 | C21H25ClN2O3 | 388.89 | C1CN(CCN1CCOCC(=O)O)C(C2=CC=CC=C2)C3=CC=C(C=C3)Cl |
| EOS-AX1013 | Cevimeline | 107233-08-9 | C10H17NOS | 199.32 | CC1OC2(CN3CCC2CC3)CS1 |
| EOS-AX1014 | Cevimeline hydrochloride hemihydrate | 153504-70-2 | C10H20ClNO2S | 253.79 | CC1OC2(CN3CCC2CC3)CS1.O.Cl |
| EOS-AX1015 | c-FMS inhibitor | 885704-21-2 | C23H30N6O | 406.52 | CC1CCN(CC1)C2=C(C=CC(=C2)N3CCN(CC3)C)NC(=O)C4=CC(=CN4)C#N |
| EOS-AX1016 | CGI-1746 | 910232-84-7 | C34H37N5O4 | 579.71 | CC1=C(C=CC=C1NC(=O)C2=CC=C(C=C2)C(C)(C)C)C3=CN(C(=O)C(=N3)NC4=CC=C(C=C4)C(=O)N5CCOCC5)C |
| EOS-AX1017 | CGP60474 | 164658-13-3 | C18H18ClN5O | 355.82 | C1=CC(=CC(=C1)Cl)NC2=NC=CC(=N2)C3=CC(=NC=C3)NCCCO |
| EOS-AX1018 | CGS 21680 | 120225-54-9 | C23H29N7O6 | 499.52 | CCNC(=O)C1C(C(C(O1)N2C=NC3=C2N=C(N=C3N)NCCC4=CC=C(C=C4)CCC(=O)O)O)O |
| EOS-AX1019 | CHAPS | 75621-03-3 | C32H58N2O7S | 614.88 | CC(CCC(=O)NCCC[N+](C)(C)CCCS(=O)(=O)[O-])C1CCC2C1(C(CC3C2C(CC4C3(CCC(C4)O)C)O)O)C |
| EOS-AX1020 | Chelerythrine Chloride | 34316-15-9 | C21H18ClNO4 | 383.83 | C[N+]1=C2C(=C3C=CC(=C(C3=C1)OC)OC)C=CC4=CC5=C(C=C42)OCO5.[Cl-] |
| EOS-AX1021 | CHIR-090 | 728865-23-4 | C24H27N3O5 | 437.49 | CC(C(C(=O)NO)NC(=O)C1=CC=C(C=C1)C#CC2=CC=C(C=C2)CN3CCOCC3)O |
| EOS-AX1022 | Choline Fenofibrate | 856676-23-8 | C22H28ClNO5 | 421.91 | CC(C([O-])=O)(OC1=CC=C(C(C2=CC=C(Cl)C=C2)=O)C=C1)C.C[N+](C)(CCO)C |
| EOS-AX1023 | CHR-6494 | 1333377-65-3 | C16H16N6 | 292.34 | CCCNC1=NN2C(=NC=C2C3=CC4=C(C=C3)NN=C4)C=C1 |
| EOS-AX1024 | chroman 1 | 1273579-40-0 | C24H28N4O4 | 436.5 | CN(C)CCOC1=C(C=CC(=C1)C2=CNN=C2)NC(=O)C3CC4=C(C=CC(=C4)OC)OC3 |
| EOS-AX1025 | CID-2858522 | 758679-97-9 | C28H39N3O3 | 465.63 | CC1=CC2=C(N(CC(C3=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C3)=O)C(NCCCO)=N2)C=C1C |
| EOS-AX1026 | Ciluprevir (BILN-2061) | 300832-84-2 | C40H50N6O8S | 774.93 | O=C(N[C@@H](CCCCC/C=C\[C@@](C1)([H])[C@]1(C(O)=O)NC2=O)C(N3[C@@]2([H])C[C@@H](OC4=CC(C5=CSC(NC(C)C)=N5)=NC6=C4C=CC(OC)=C6)C3)=O)OC7CCCC7 |
| EOS-AX1027 | Cinacalcet | 226256-56-0 | C22H22F3N | 357.41 | CC(C1=CC=CC2=CC=CC=C21)NCCCC3=CC(=CC=C3)C(F)(F)F |
| EOS-AX1028 | Cinaciguat | 329773-35-5 | C36H39NO5 | 565.7 | C1=CC=C(C=C1)CCC2=CC=C(C=C2)COC3=CC=CC=C3CCN(CCCCC(=O)O)CC4=CC=C(C=C4)C(=O)O |
| EOS-AX1029 | Clemizole | 442-52-4 | C19H20ClN3 | 325.84 | C1CCN(C1)CC2=NC3=CC=CC=C3N2CC4=CC=C(C=C4)Cl |
| EOS-AX1030 | Clemizole hydrochloride | 1163-36-6 | C19H21Cl2N3 | 362.3 | C1CCN(C1)CC2=NC3=CC=CC=C3N2CC4=CC=C(C=C4)Cl.Cl |
| EOS-AX1031 | Clozapine N-oxide (CNO) | 34233-69-7 | C18H19ClN4O | 342.82 | C[N+]1(CCN(CC1)C2=C3C=CC=CC3=NC4=C(N2)C=C(C=C4)Cl)[O-] |
| EOS-AX1032 | c-Met inhibitor 1 | 1357072-61-7 | C17H14N8S | 362.41 | CN1C=C(C=N1)C2=NN3C(=NN=C3SC4=CC5=CN(N=C5C=C4)C)C=C2 |
| EOS-AX1033 | CMK | 821794-90-5 | C18H19ClN4O2 | 358.83 | CC1=CC=C(C=C1)C2=C(N(C3=C2C(=NC=N3)N)CCCO)C(=O)CCl |
| EOS-AX1034 | CO-1686 (AVL-301) | 1374640-70-6 | C27H28F3N7O3 | 555.55 | CC(=O)N1CCN(CC1)C2=CC(=C(C=C2)NC3=NC=C(C(=N3)NC4=CC(=CC=C4)NC(=O)C=C)C(F)(F)F)OC |
| EOS-AX1035 | Cobimetinib | 934660-93-2 | C21H21F3IN3O2 | 531.31 | C1CCNC(C1)C2(CN(C2)C(=O)C3=C(C(=C(C=C3)F)F)NC4=C(C=C(C=C4)I)F)O |
| EOS-AX1036 | Cobimetinib (racemate) | 934662-91-6 | C21H21F3IN3O2 | 531.31 | C1CCNC(C1)C2(CN(C2)C(=O)C3=C(C(=C(C=C3)F)F)NC4=C(C=C(C=C4)I)F)O |
| EOS-AX1037 | Cobimetinib (R-enantiomer) | 934660-94-3 | C21H21F3IN3O2 | 531.31 | C1CCNC(C1)C2(CN(C2)C(=O)C3=C(C(=C(C=C3)F)F)NC4=C(C=C(C=C4)I)F)O |
| EOS-AX1038 | Colchicine | 64-86-8 | C22H25NO6 | 399.44 | CC(=O)NC1CCC2=CC(=C(C(=C2C3=CC=C(C(=O)C=C13)OC)OC)OC)OC |
| EOS-AX1039 | Collagen proline hydroxylase inhibitor | 223666-07-7 | C18H18N4O4 | 354.36 | CCCN(C(C1=CN=C2C(C=CC3=C2NC=C([N+]([O-])=O)C3=O)=C1)=O)CC |
| EOS-AX1040 | Collagen proline hydroxylase inhibitor-1 | 223663-32-9 | C24H21N5O4 | 443.45 | O=C(C1=CN=C2C(C=CC3=C2NC=C([N+]([O-])=O)C3=O)=C1)N4CCN(CC5=CC=CC=C5)CC4 |
| EOS-AX1041 | Costunolide | 553-21-9 | C15H20O2 | 232.32 | CC1=CCCC(=CC2C(CC1)C(=C)C(=O)O2)C |
| EOS-AX1042 | Cot inhibitor-1 | 915365-57-0 | C27H27Cl2FN8 | 553.47 | C1CCCN(CC1)CCN2C=C(N=N2)CNC3=CC(=C4C(=C3)C(=C(C=N4)C#N)NC5=CC(=C(C=C5)F)Cl)Cl |
| EOS-AX1043 | Cot inhibitor-2 | 915363-56-3 | C26H25Cl2FN8 | 539.45 | CCN1CCC(CC1)N2C=C(N=N2)CNC3=CC(=C4C(=C3)C(=C(C=N4)C#N)NC5=CC(=C(C=C5)F)Cl)Cl |
| EOS-AX1044 | CP-809101 | 479683-64-2 | C15H17ClN4O | 304.77 | ClC1=CC=CC(COC2=NC(N3CCNCC3)=CN=C2)=C1 |
| EOS-AX1045 | CP-809101 hydrochloride | 1215721-40-6 | C15H18Cl2N4O | 341.24 | C1CN(CCN1)C2=CN=CC(=N2)OCC3=CC(=CC=C3)Cl.Cl |
| EOS-AX1046 | CPA inhibitor | 223532-02-3 | C18H19NO4 | 313.36 | C1=CC=C(C=C1)CC(CN(C(=O)CC2=CC=CC=C2)O)C(=O)O |
| EOS-AX1047 | CPPHA | 693288-97-0 | C22H15ClN2O4 | 406.82 | O=C(N1CC2=C(NC(C3=CC=CC=C3O)=O)C=CC(Cl)=C2)C4=CC=CC=C4C1=O |
| EOS-AX1048 | CTS-1027 | 193022-04-7 | C19H20ClNO6S | 425.88 | C1COCCC1(CS(=O)(=O)C2=CC=C(C=C2)OC3=CC=C(C=C3)Cl)C(=O)NO |
| EOS-AX1049 | Curcumin | 458-37-7 | C21H20O6 | 368.38 | COC1=C(C=CC(=C1)C=CC(=O)CC(=O)C=CC2=CC(=C(C=C2)O)OC)O |
| EOS-AX1050 | CVT-313 | 199986-75-9 | C20H28N6O3 | 400.47 | CC(C)N1C=NC2=C1N=C(N=C2NCC3=CC=C(C=C3)OC)N(CCO)CCO |
| EOS-AX1051 | CX-6258 | 1202916-90-2 | C26H24ClN3O3 | 461.94 | CN1CCCN(C(C2=CC(C3=CC=C(/C=C4C(C=C(Cl)C=C5)=C5NC\4=O)O3)=CC=C2)=O)CC1 |
| EOS-AX1052 | CX-6258 hydrochloride hydrate | 1353858-99-7 | C26H27Cl2N3O4 | 516.42 | CN1CCCN(C(C2=CC=CC(C3=CC=C(O3)/C([H])=C(C(O)=N4)\C5=C4C=CC(Cl)=C5)=C2)=O)CC1.Cl.O |
| EOS-AX1053 | CYT387 sulfate salt | 1056636-06-6 | C23H26N6O10S2 | 610.62 | C1COCCN1C2=CC=C(C=C2)NC3=NC=CC(=N3)C4=CC=C(C=C4)C(=O)NCC#N.OS(=O)(=O)O.OS(=O)(=O)O |
| EOS-AX1054 | CZC24832 | 1159824-67-5 | C15H17FN6O2S | 364.4 | CC(C)(C)NS(=O)(=O)C1=CN=CC(=C1)C2=CN3C(=NC(=N3)N)C(=C2)F |
| EOS-AX1055 | D149 Dye | 786643-20-7 | C42H35N3O4S3 | 741.96 | CCN1C(=O)C(=C2N(C(=O)C(=CC3=CC4=C(C=C3)N(C5C4CCC5)C6=CC=C(C=C6)C=C(C7=CC=CC=C7)C8=CC=CC=C8)S2)CC(=O)O)SC1=S |
| EOS-AX1056 | D4476 | 301836-43-1 | C23H18N4O3 | 398.41 | C1COC2=C(O1)C=CC(=C2)C3=C(NC(=N3)C4=CC=C(C=C4)C(=O)N)C5=CC=CC=N5 |
| EOS-AX1057 | D609 | 83373-60-8 | C11H15KOS2 | 266.47 | S=C(S[K])OC1CC2C3C(CCC3)C1C2 |
| EOS-AX1058 | D-64131 | 74588-78-6 | C16H13NO2 | 251.28 | COC1=CC2=C(C=C1)NC(=C2)C(=O)C3=CC=CC=C3 |
| EOS-AX1059 | Dabigatran etexilate mesylate | 872728-81-9 | C35H45N7O8S | 723.84 | CCCCCCOC(NC(C1=CC=C(NCC2=NC3=C(C=CC(C(N(C4=CC=CC=N4)CCC(OCC)=O)=O)=C3)N2C)C=C1)=N)=O.CS(=O)(O)=O |
| EOS-AX1060 | Dabigatran ethyl ester | 429658-95-7 | C27H29N7O3 | 499.56 | CCOC(CCN(C(C1=CC2=C(N(C)C(CNC3=CC=C(C(N)=N)C=C3)=N2)C=C1)=O)C4=CC=CC=N4)=O |
| EOS-AX1061 | Dabrafenib Mesylate (GSK-2118436) | 1195768-06-9 | C24H24F3N5O5S3 | 615.67 | CC(C)(C)C1=NC(=C(S1)C2=NC(=NC=C2)N)C3=C(C(=CC=C3)NS(=O)(=O)C4=C(C=CC=C4F)F)F.CS(=O)(=O)O |
| EOS-AX1062 | Daminozide | 1596-84-5 | C6H12N2O3 | 160.17 | CN(C)NC(=O)CCC(=O)O |
| EOS-AX1063 | Darapladib | 356057-34-6 | C36H38F4N4O2S | 666.77 | CCN(CC)CCN(CC1=CC=C(C=C1)C2=CC=C(C=C2)C(F)(F)F)C(=O)CN3C4=C(CCC4)C(=O)N=C3SCC5=CC=C(C=C5)F |
| EOS-AX1064 | Darifenacin | 133099-04-4 | C28H30N2O2 | 426.55 | C1CN(CC1C(C2=CC=CC=C2)(C3=CC=CC=C3)C(=O)N)CCC4=CC5=C(C=C4)OCC5 |
| EOS-AX1065 | Dasatinib hydrochloride | 854001-07-3 | C22H27Cl2N7O2S | 524.47 | CC1=C(/N=C(O)/C(S2)=CN=C2NC3=CC(N4CCN(CCO)CC4)=NC(C)=N3)C(Cl)=CC=C1.Cl |
| EOS-AX1066 | Daun02 | 290304-24-4 | C41H44N2O20 | 884.79 | CC1C(C(CC(O1)OC2CC(CC3=C(C4=C(C(=C23)O)C(=O)C5=C(C4=O)C=CC=C5OC)O)(C(=O)C)O)NC(=O)OCC6=CC(=C(C=C6)OC7C(C(C(C(O7)CO)O)O)O)[N+](=O)[O-])O |
| EOS-AX1067 | DB07268 | 929007-72-7 | C17H15N5O2 | 321.33 | C1=CC=C(C(=C1)C(=O)N)NC2=NC(=NC=C2)NC3=CC(=CC=C3)O |
| EOS-AX1068 | DCC-2618 | 1225278-16-9 | C26H21F2N5O3 | 489.47 | CN1C=C(C=N1)C2=NC=CC(=C2)OC3=C(C=C(C(=C3)F)NC(=O)C4(CC4)C(=O)NC5=CC=CC=C5)F |
| EOS-AX1069 | Deferasirox Fe3+ chelate | 554435-83-5 | C21H12FeN3O4 | 426.18 | C1=CC=C(C(=C1)C2=NN(C(=N2)C3=CC=CC=C3[O-])C4=CC=C(C=C4)C(=O)[O-])[O-].[Fe+3] |
| EOS-AX1070 | Delafloxacin | 189279-58-1 | C18H12ClF3N4O4 | 440.76 | ClC1=C(N(C2=NC(N)=C(F)C=C2F)C=C(C(O)=O)C3=O)C3=CC(F)=C1N4CC(O)C4 |
| EOS-AX1071 | Delafloxacin meglumine | 352458-37-8 | C25H29ClF3N5O9 | 635.97 | CNCC(C(C(C(CO)O)O)O)O.C1C(CN1C2=C(C=C3C(=C2Cl)N(C=C(C3=O)C(=O)O)C4=NC(=C(C=C4F)F)N)F)O |
| EOS-AX1072 | Deltarasin | 1440898-61-2 | C40H37N5O | 603.75 | [H][C@@](C1CCNCC1)(N2C3=CC=CC=C3N=C2C4=CC=CC=C4)COC5=CC=C(C6=NC7=CC=CC=C7N6CC8=CC=CC=C8)C=C5 |
| EOS-AX1073 | Desmopressin | 16679-58-6 | C46H64N14O12S2 | 1069.22 | O=C(C1CSSCCC(NC(CC2=CC=C(O)C=C2)C(NC(CC3=CC=CC=C3)C(NC(CCC(N)=O)C(NC(CC(N)=O)C(N1)=O)=O)=O)=O)=O)N4C(C(NC(C(NCC(N)=O)=O)CCC/N=C(N)\N)=O)CCC4 |
| EOS-AX1074 | Desmopressin Acetate | 62288-83-9 | C48H68N14O14S2 | 1129.27 | CC(=O)O.C1CC(N(C1)C(=O)C2CSSCCC(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)C(=O)NC(CCCN=C(N)N)C(=O)NCC(=O)N |
| EOS-AX1075 | Dexpramipexole | 104632-28-2 | C10H17N3S | 211.33 | CCCNC1CCC2=C(SC(N)=N2)C1 |
| EOS-AX1076 | Dexpramipexole dihydrochloride | 104632-27-1 | C10H19Cl2N3S | 284.25 | CCCNC1CCC2=C(SC(N)=N2)C1.Cl.Cl |
| EOS-AX1077 | DGAT-1 inhibitor | 701232-20-4 | C22H26N4O3 | 394.2 | CC1(C(=NC2=C(N=CN=C2O1)N)C3=CC=C(C=C3)C4CCC(CC4)CC(=O)O)C |
| EOS-AX1078 | DGAT-1 inhibitor 2 | 942999-61-3 | C24H28N4O3 | 420.5 | CC1(C(=NC2=C(N=CN=C2O1)N)C3=CC=C(C=C3)C45CCC(CC4)(CC5)CC(=O)O)C |
| EOS-AX1079 | Diazepam | 439-14-5 | C16H13ClN2O | 284.74 | |
| EOS-AX1080 | Dipraglurant | 872363-17-2 | C16H12FN3 | 265.29 | C1=CC=NC(=C1)C#CCCC2=CN3C=C(C=CC3=N2)F |
| EOS-AX1081 | DMA | 188860-26-6 | C27H28N6O2 | 468.55 | |
| EOS-AX1082 | DMAT | 749234-11-5 | C9H7Br4N3 | 476.79 | CN(C)C1=NC2=C(N1)C(=C(C(=C2Br)Br)Br)Br |
| EOS-AX1083 | DMP 777 | 157341-41-8 | C31H40N4O6 | 564.69 | CCCC(C1=CC2=C(C=C1)OCO2)NC(=O)N3C(C(C3=O)(CC)CC)OC4=CC=C(C=C4)C(=O)N5CCN(CC5)C |
| EOS-AX1084 | Docetaxel Trihydrate | 148408-66-6 | C43H59NO17 | 861.93 | CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O.O.O.O |
| EOS-AX1085 | Doramectin | 117704-25-3 | C50H74O14 | 899.11 | CC1/C=C/C=C2COC3C\2(O)C(C(OC4CC(OC5(C=CC(C)C(C6CCCCC6)O5)C4)C/C=C(C)/C1OC7CC(OC)C(OC8CC(OC)C(O)C(C)O8)C(C)O7)=O)C=C(C)C3O |
| EOS-AX1086 | DOXO-EMCH | 151038-96-9 | C37H42N4O13 | 750.75 | CC1C(C(CC(O1)OC2CC(CC3=C(C4=C(C(=C23)O)C(=O)C5=C(C4=O)C=CC=C5OC)O)(C(=NNC(=O)CCCCCN6C(=O)C=CC6=O)CO)O)N)O |
| EOS-AX1087 | DPH | 484049-04-9 | C18H13FN4O2 | 336.33 | C1=CC=C(C=C1)N2C=C(C(=N2)C3=CC=C(C=C3)F)C4C(=O)NC(=O)N4 |
| EOS-AX1088 | Dronedarone | 141626-36-0 | C31H44N2O5S | 556.77 | CCCCC1=C(C2=C(O1)C=CC(=C2)NS(=O)(=O)C)C(=O)C3=CC=C(C=C3)OCCCN(CCCC)CCCC |
| EOS-AX1089 | DY131 | 95167-41-2 | C18H21N3O2 | 311.38 | CCN(CC)C1=CC=C(C=C1)C=NNC(=O)C2=CC=C(C=C2)O |
| EOS-AX1090 | Dye 937 | 195199-04-3 | C32H37IN4S | 636.63 | CCCN(CCCN(C)C)C1=[N+](C2=CC=CC=C2C(=C1)C=C3N(C4=CC=CC=C4S3)C)C5=CC=CC=C5.[I-] |
| EOS-AX1091 | E 2012 | 870843-42-8 | C25H26FN3O2 | 419.49 | CC1=CN(C=N1)C2=C(C=C(C=C2)C=C3CCCN(C3=O)C(C)C4=CC=C(C=C4)F)OC |
| EOS-AX1092 | E-3810 | 1058137-23-7 | C26H25N3O4 | 443.49 | CNC(=O)C1=CC=CC2=C1C=CC(=C2)OC3=C4C=C(C(=CC4=NC=C3)OCC5(CC5)N)OC |
| EOS-AX1093 | EBE-A22 | 229476-53-3 | C17H16BrN3O2 | 374.23 | CN(C1=CC(=CC=C1)Br)C2=NC=NC3=CC(=C(C=C32)OC)OC |
| EOS-AX1094 | Ebrotidine | 100981-43-9 | C14H17BrN6O2S3 | 477.42 | C1=CC(=CC=C1S(=O)(=O)NC=NCCSCC2=CSC(=N2)N=C(N)N)Br |
| EOS-AX1095 | Edoxaban | 480449-70-5 | C24H30ClN7O4S | 548.06 | CN1CCC2=C(C1)SC(=N2)C(=O)NC3CC(CCC3NC(=O)C(=O)NC4=NC=C(C=C4)Cl)C(=O)N(C)C |
| EOS-AX1096 | Edoxaban tosylate | 480449-71-6 | C31H38ClN7O7S2 | 720.26 | CC1=CC=C(S(=O)(O)=O)C=C1.CN2CCC3=C(SC(C(NC4CC(C(N(C)C)=O)CCC4NC(C(NC5=NC=C(Cl)C=C5)=O)=O)=O)=N3)C2 |
| EOS-AX1097 | Edoxaban tosylate monohydrate | 1229194-11-9 | C31H40ClN7O8S2 | 738.27 | CC1=CC=C(C=C1)S(=O)(=O)O.CN1CCC2=C(C1)SC(=N2)C(=O)NC3CC(CCC3NC(=O)C(=O)NC4=NC=C(C=C4)Cl)C(=O)N(C)C.O |
| EOS-AX1098 | Elacridar | 143664-11-3 | C34H33N3O5 | 563.64 | COC1=CC=CC2=C1NC3=C(C2=O)C=CC=C3C(=O)NC4=CC=C(C=C4)CCN5CCC6=CC(=C(C=C6C5)OC)OC |
| EOS-AX1099 | Elacridar hydrochloride | 143851-98-3 | C34H34ClN3O5 | 600.1 | COC1=CC=CC2=C1NC3=C(C2=O)C=CC=C3C(=O)NC4=CC=C(C=C4)CCN5CCC6=CC(=C(C=C6C5)OC)OC.Cl |
| EOS-AX1100 | Eldecalcitol | 104121-92-8 | C30H50O5 | 490.72 | CC(CCCC(C)(C)O)C1CCC2C1(CCCC2=CC=C3CC(C(C(C3=C)O)OCCCO)O)C |
| EOS-AX1101 | Eltrombopag Olamine | 496775-62-3 | C29H36N6O6 | 564.63 | CC1=C(C=C(C=C1)N2C(=O)C(=C(N2)C)NN=C3C=CC=C(C3=O)C4=CC(=CC=C4)C(=O)O)C.C(CO)N.C(CO)N |
| EOS-AX1102 | EMD-1214063 | 1100598-32-0 | C29H28N6O2 | 492.57 | CN1CCC(CC1)COC2=CN=C(N=C2)C3=CC(=CC=C3)CN4C(=O)C=CC(=N4)C5=CC=CC(=C5)C#N |
| EOS-AX1103 | EMD638683 | 1181770-72-8 | C18H18F2N2O4 | 364.34 | CCC1=C(C=CC(=C1C)O)C(=O)NNC(=O)C(C2=CC(=CC(=C2)F)F)O |
| EOS-AX1104 | EMD638683 R-Form | 1184940-47-3 | C18H18F2N2O4 | 364.34 | CCC1=C(C=CC(=C1C)O)C(=O)NNC(=O)C(C2=CC(=CC(=C2)F)F)O |
| EOS-AX1105 | EMD638683 S-Form | 1184940-46-2 | C18H18F2N2O4 | 364.34 | CCC1=C(C=CC(=C1C)O)C(=O)NNC(=O)C(C2=CC(=CC(=C2)F)F)O |
| EOS-AX1106 | Emodin | 518-82-1 | C15H10O5 | 270.24 | CC1=CC(O)=C2C(C(C3=CC(O)=CC(O)=C3C2=O)=O)=C1 |
| EOS-AX1107 | Episilvestrol | 697235-39-5 | C34H38O13 | 654.66 | |
| EOS-AX1108 | Epothilone D | 189453-10-9 | C27H41NO5S | 491.68 | CC1CCCC(=CCC(OC(=O)CC(C(C(=O)C(C1O)C)(C)C)O)C(=CC2=CSC(=N2)C)C)C |
| EOS-AX1109 | Ercalcidiol | 21343-40-8 | C28H44O2 | 412.66 | CC(C=CC(C)C(C)(C)O)C1CCC2C1(CCCC2=CC=C3CC(CCC3=C)O)C |
| EOS-AX1110 | Ercalcitriol | 60133-18-8 | C28H44O3 | 428.66 | CC(C=CC(C)C(C)(C)O)C1CCC2C1(CCCC2=CC=C3CC(CC(C3=C)O)O)C |
| EOS-AX1111 | Erlotinib | 183321-74-6 | C22H23N3O4 | 393.44 | COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC |
| EOS-AX1112 | Erlotinib mesylate | 248594-19-6 | C23H27N3O7S | 489.54 | COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC.CS(=O)(=O)O |
| EOS-AX1113 | Esomeprazole Magnesium trihydrate | 217087-09-7 | C34H42MgN6O9S2 | 767.17 | CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C([N-]2)C=CC(=C3)OC.CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C([N-]2)C=CC(=C3)OC.O.O.O.[Mg+2] |
| EOS-AX1114 | Etifoxine | 21715-46-8 | C17H17ClN2O | 300.78 | CCNC1=NC2=C(C=C(C=C2)Cl)C(O1)(C)C3=CC=CC=C3 |
| EOS-AX1115 | Etifoxine hydrochloride | 56776-32-0 | C17H18Cl2N2O | 337.24 | CCNC1=NC2=C(C=C(C=C2)Cl)C(O1)(C)C3=CC=CC=C3.Cl |
| EOS-AX1116 | Etimizol | 64-99-3 | C9H14N4O2 | 210.23 | CCN1C=NC(=C1C(=O)NC)C(=O)NC |
| EOS-AX1117 | Etofenamate | 30544-47-9 | C18H18F3NO4 | 369.34 | C1=CC=C(C(=C1)C(=O)OCCOCCO)NC2=CC=CC(=C2)C(F)(F)F |
| EOS-AX1118 | Etomoxir | 124083-20-1 | C17H23ClO4 | 326.82 | CCOC(=O)C1(CO1)CCCCCCOC2=CC=C(C=C2)Cl |
| EOS-AX1119 | Etoricoxib | 202409-33-4 | C18H15ClN2O2S | 358.84 | CC1=NC=C(C=C1)C2=NC=C(C=C2C3=CC=C(C=C3)S(=O)(=O)C)Cl |
| EOS-AX1120 | EVP-6124 | 550999-75-2 | C16H17ClN2OS | 320.84 | O=C(C1=CC2=C(C(Cl)=CC=C2)S1)NC(C3)C4CCN3CC4 |
| EOS-AX1121 | EVP-6124 hydrochloride | 550999-74-1 | C16H18Cl2N2OS | 357.3 | C1CN2CCC1C(C2)NC(=O)C3=CC4=C(S3)C(=CC=C4)Cl.Cl |
| EOS-AX1122 | Exendin-4 | 141758-74-9 | C184H282N50O60S | 4186.57 | CCC(C)C(C(=O)NC(CCC(=O)O)C(=O)NC(CC1=CNC2=CC=CC=C21)C(=O)NC(CC(C)C)C(=O)NC(CCCCN)C(=O)NC(CC(=O)N)C(=O)NCC(=O)NCC(=O)N3CCCC3C(=O)NC(CO)C(=O)NC(CO)C(=O)NCC(=O)NC(C)C(=O)N4CCCC4C(=O)N5CCCC5C(=O)N6CCCC6C(=O)NC(CO)C(=O)N)NC(=O)C(CC7=CC=CC=C7)NC(=O)C(CC(C)C)NC( |
| EOS-AX1123 | Fagomine | 53185-12-9 | C6H13NO3 | 147.18 | C1CNC(C(C1O)O)CO |
| EOS-AX1124 | Falecalcitriol | 83805-11-2 | C27H38F6O3 | 524.58 | CC(CCCC(C(F)(F)F)(C(F)(F)F)O)C1CCC2C1(CCCC2=CC=C3CC(CC(C3=C)O)O)C |
| EOS-AX1125 | Faropenem daloxate | 141702-36-5 | C17H19NO8S | 397.41 | CC1=C(OC(=O)O1)COC(=O)C2=C(SC3N2C(=O)C3C(C)O)C4CCCO4 |
| EOS-AX1126 | Fenretinide | 65646-68-6 | C26H33NO2 | 391.55 | CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(=CC(=O)NC2=CC=C(C=C2)O)C)C |
| EOS-AX1127 | FH535 | 108409-83-2 | C13H10Cl2N2O4S | 361.2 | CC1=C(C=CC(=C1)[N+](=O)[O-])NS(=O)(=O)C2=C(C=CC(=C2)Cl)Cl |
| EOS-AX1128 | Fiacitabine | 69123-90-6 | C9H11FIN3O4 | 371.11 | C1=C(C(=NC(=O)N1C2C(C(C(O2)CO)O)F)N)I |
| EOS-AX1129 | Firategrast | 402567-16-2 | C27H27F2NO6 | 499.5 | CCOCC1=CC(=C(C(=C1)OC)C2=CC=C(C=C2)CC(C(=O)O)NC(=O)C3=C(C=CC=C3F)F)OC |
| EOS-AX1130 | FK 3311 | 116686-15-8 | C15H13F2NO4S | 341.33 | CC(=O)C1=CC(=C(C=C1)NS(=O)(=O)C)OC2=C(C=C(C=C2)F)F |
| EOS-AX1131 | Flavopiridol | 146426-40-6 | C21H20ClNO5 | 401.85 | CN1CCC(C(C1)O)C2=C(C=C(C3=C2OC(=CC3=O)C4=CC=CC=C4Cl)O)O |
| EOS-AX1132 | Flecainide acetate | 54143-56-5 | C19H24F6N2O5 | 474.39 | CC(=O)O.C1CCNC(C1)CNC(=O)C2=C(C=CC(=C2)OCC(F)(F)F)OCC(F)(F)F |
| EOS-AX1133 | Fluvastatin | 93957-54-1 | C24H26FNO4 | 411.47 | CC(C)N1C2=CC=CC=C2C(=C1C=CC(CC(CC(=O)O)O)O)C3=CC=C(C=C3)F |
| EOS-AX1134 | FMK | 821794-92-7 | C18H19FN4O2 | 342.37 | CC1=CC=C(C=C1)C2=C(N(C3=C2C(=NC=N3)N)CCCO)C(=O)CF |
| EOS-AX1135 | Fosamprenavir Calcium Salt | 226700-81-8 | C25H34CaN3O9PS | 623.67 | CC(C)CN(CC(C(CC1=CC=CC=C1)NC(=O)OC2CCOC2)OP(=O)([O-])[O-])S(=O)(=O)C3=CC=C(C=C3)N.[Ca+2] |
| EOS-AX1136 | Furagin | 1672-88-4 | C10H8N4O5 | 264.19 | C1C(=O)NC(=O)N1N=CC=CC2=CC=C(O2)[N+](=O)[O-] |
| EOS-AX1137 | Galanthamine | 357-70-0 | C17H21NO3 | 287.35 | [H][C@@]([C@@]1(C([H])=C2[H])C3=C(C([H])=C4[H])C([H])([H])N(C([H])([H])[H])C([H])([H])C1([H])[H])(C([H])([H])[C@@]2([H])O[H])OC3=C4OC([H])([H])[H] |
| EOS-AX1138 | Gambogic Acid | 2752-65-0 | C38H44O8 | 628.75 | C/C(C)=C\CC[C@]1(C)C=CC(C(O)=C(C(C([C@]2([C@@H](C3)C(C)(C)O[C@]24C/C=C(C(O)=O)/C)O5)=C[C@H]3C4=O)=O)C5=C6C/C=C(C)\C)=C6O1 |
| EOS-AX1139 | gamma-secretase modulator 1 | 1172637-87-4 | C24H24N4OS | 416.54 | CC1=CN(C=N1)C2=C(C=C(C=C2)NC3=NC4=C(S3)CCCC4C5=CC=CC=C5)OC |
| EOS-AX1140 | gamma-secretase modulator 2 | 1093978-89-2 | C25H22F4N6O2 | 514.47 | CC1=CN(C=N1)C2=C(C=C(C=C2)C3=CN(N=N3)C4CCC5=C(C=CC=C5F)N(C4=O)CC(F)(F)F)OC |
| EOS-AX1141 | gamma-secretase modulator 3 | 1431697-84-5 | C24H23FN4OS | 434.53 | CC1=CN(C2=C(OC)C=C(NC3=NC4=C(CCC[C@@H]4C5=CC=C(F)C=C5)S3)C=C2)C=N1 |
| EOS-AX1142 | gamma-Secretase Modulators | 937812-80-1 | C26H24F3N3O3 | 483.49 | CC1=CN(C=N1)C2=C(C=C(C=C2)C=C3CCC4COCC(N4C3=O)C5=CC(=C(C(=C5)F)F)F)OC |
| EOS-AX1143 | GANT 58 | 64048-12-0 | C24H16N4S | 392.48 | C1=CN=CC=C1C2=C(SC(=C2C3=CC=NC=C3)C4=CC=NC=C4)C5=CC=NC=C5 |
| EOS-AX1144 | GAP-134 | 943134-39-2 | C14H17N3O4 | 291.3 | O=C(O)C1N(C(CN)=O)CC(NC(C2=CC=CC=C2)=O)C1 |
| EOS-AX1145 | GAP-134 Hydrochloride | 943133-81-1 | C14H18ClN3O4 | 327.76 | C1C(CN(C1C(=O)O)C(=O)CN)NC(=O)C2=CC=CC=C2.Cl |
| EOS-AX1146 | GDC-0941 dimethanesulfonate | 957054-33-0 | C25H35N7O9S4 | 705.85 | CS(=O)(=O)N1CCN(CC1)CC2=CC3=C(S2)C(=NC(=N3)C4=C5C=NNC5=CC=C4)N6CCOCC6.CS(=O)(=O)O.CS(=O)(=O)O |
| EOS-AX1147 | Gefitinib hydrochloride | 184475-55-6 | C22H25Cl2FN4O3 | 483.36 | COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4.Cl |
| EOS-AX1148 | Genz-644282 | 529488-28-6 | C22H21N3O5 | 407.42 | O=C1N(C([H])([H])C([H])([H])N([H])C([H])([H])[H])C(C(C(N=C2[H])=C3[H])=C([H])C4=C3OC([H])([H])O4)=C2C(C1=C5[H])=C([H])C(OC([H])([H])[H])=C5OC([H])([H])[H] |
| EOS-AX1149 | glucagon receptor antagonists 1 | 503559-84-0 | C29H34FNO2 | 447.6 | CC=CC1=C(C(=C(N=C1C(C)C)C(C)C)C(C)O)C2=C(C=C(C=C2)F)OCC3=CC=CC=C3 |
| EOS-AX1150 | glucagon receptor antagonists 2 | 202917-18-8 | C22H30FNO2 | 359.49 | CCCC1=C(NC(=C(C1C2=C(C=C(C=C2)F)O)C(C)O)C(C)C)C(C)C |
| EOS-AX1151 | glucagon receptor antagonists 3 | 202917-17-7 | C22H32FNO2 | 361.49 | CCCC([C@@](C([C@@](O)([H])C)=C1C(C)C)([H])C2=C(O)C=C(F)C=C2)=C(N1)C(C)C |
| EOS-AX1152 | Glucocorticoid receptor agonist | 1245526-82-2 | C20H20F4N2O2 | 396.38 | CC(C)(CC(CC1=CC2=C(N1)C=NC=C2)(C(F)(F)F)O)C3=C(C=CC(=C3)F)O |
| EOS-AX1153 | Glucose-conjugated MGMT inhibitor | 382607-78-5 | C24H34BrN5O7S | 616.53 | C1=C(SC=C1Br)COC2=NC(=NC3=C2N=CN3CCCCCCCCOC4C(C(C(C(O4)CO)O)O)O)N |
| EOS-AX1154 | Glyoxalase I inhibitor | 221174-33-0 | C21H30BrClN4O8S | 613.91 | CCOC(=O)CNC(=O)C(CSC(=O)N(C1=CC=C(C=C1)Br)O)NC(=O)CCC(C(=O)OCC)N.Cl |
| EOS-AX1155 | GPR120 modulator 1 | 1050506-75-6 | C19H16ClNO4S | 389.85 | CC1=C(C=CC(=C1)OCC2=NC(=CS2)C3=CC=CC=C3Cl)OCC(=O)O |
| EOS-AX1156 | GPR120 modulator 2 | 1050506-87-0 | C20H18ClNO3S | 387.88 | CC1=C(C=CC(=C1)OCC2=NC(=CS2)C3=CC=CC=C3Cl)CCC(=O)O |
| EOS-AX1157 | Granisetron | 109889-09-0 | C18H24N4O | 312.41 | CN1C2CCCC1CC(C2)NC(=O)C3=NN(C4=CC=CC=C43)C |
| EOS-AX1158 | GS-9620 | 1228585-88-3 | C22H30N6O2 | 410.51 | CCCCOC1=NC2=C(C(=N1)N)NC(=O)CN2CC3=CC(=CC=C3)CN4CCCC4 |
| EOS-AX1159 | GSK 525768A | 1260530-25-3 | C22H22ClN5O2 | 423.9 | CCNC(=O)CC1C2=NN=C(N2C3=C(C=C(C=C3)OC)C(=N1)C4=CC=C(C=C4)Cl)C |
| EOS-AX1160 | GSK126 | 1346574-57-9 | C31H38N6O2 | 526.67 | CCC(C)N1C=C(C2=C(C=C(C=C21)C3=CN=C(C=C3)N4CCNCC4)C(=O)NCC5=C(C=C(NC5=O)C)C)C |
| EOS-AX1161 | GSK256066 2,2,2-trifluoroacetic acid | 1415560-64-3 | C29H27F3N4O7S | 632.61 | CC1=C2C(=CC(=C1)S(=O)(=O)C3=CC=CC(=C3)C(=O)N(C)C)C(=C(C=N2)C(=O)N)NC4=CC(=CC=C4)OC.C(=O)(C(F)(F)F)O |
| EOS-AX1162 | GSK2606414 | 1337531-36-8 | C24H20F3N5O | 451.44 | CN1C=C(C2=C1N=CN=C2N)C3=CC4=C(C=C3)N(CC4)C(=O)CC5=CC(=CC=C5)C(F)(F)F |
| EOS-AX1163 | GSK343 | 1346704-33-3 | C31H39N7O2 | 541.69 | CCCC1=C(C(=O)NC(=C1)C)CNC(=O)C2=C3C=NN(C3=CC(=C2)C4=CC(=NC=C4)N5CCN(CC5)C)C(C)C |
| EOS-AX1164 | GSK-923295 | 1088965-37-0 | C32H38ClN5O4 | 592.14 | CC(C)OC1=C(C=C(C=C1)C(=O)NC(CC2=CC=C(C=C2)C3=CN4C=CC=C(C4=N3)C(C)O)CNC(=O)CN(C)C)Cl |
| EOS-AX1165 | Guanfacine hydrochloride | 29110-48-3 | C9H10Cl3N3O | 282.55 | C1=CC(=C(C(=C1)Cl)CC(=O)N=C(N)N)Cl.Cl |
| EOS-AX1166 | GW-1100 | 306974-70-9 | C27H25FN4O4S | 520.59 | CCOC1=NC=C(C=N1)CC2=CN(C(=NC2=O)SCC3=CC=C(C=C3)F)C4=CC=C(C=C4)C(=O)OCC |
| EOS-AX1167 | GW1929 | 196808-24-9 | C30H29N3O4 | 495.57 | CN(C1=CC=CC=N1)CCOC2=CC=C(CC(NC3=CC=CC=C3C(C4=CC=CC=C4)=O)C(O)=O)C=C2 |
| EOS-AX1168 | GW3965 | 405911-09-3 | C33H31ClF3NO3 | 582.05 | C1=CC=C(C=C1)C(CN(CCCOC2=CC=CC(=C2)CC(=O)O)CC3=C(C(=CC=C3)C(F)(F)F)Cl)C4=CC=CC=C4 |
| EOS-AX1169 | GW791343 dihydrochloride | 1019779-04-4 | C20H26Cl2F2N4O | 447.35 | CC1=C(/N=C(O)/CNC2=CC(F)=C(F)C=C2)C=C(CN3CCNCC3)C=C1.Cl.Cl |
| EOS-AX1170 | GW843682X | 660868-91-7 | C22H18F3N3O4S | 477.46 | COC1=C(C=C2C(=C1)N=CN2C3=CC(=C(S3)C(=O)N)OCC4=CC=CC=C4C(F)(F)F)OC |
| EOS-AX1171 | H-1152 | 451462-58-1 | C16H21N3O2S | 319.42 | CC1=C2C(C=CC=C2S(N3CCCNC[C@]3([H])C)(=O)=O)=CN=C1 |
| EOS-AX1172 | H-1152 dihydrochloride | 871543-07-6 | C16H23Cl2N3O2S | 392.34 | CC1CNCCCN1S(=O)(C2=CC=CC3=CN=CC(C)=C32)=O.Cl.Cl |
| EOS-AX1173 | HA14-1 | 65673-63-4 | C17H17BrN2O5 | 409.24 | |
| EOS-AX1174 | HhAntag | 496794-70-8 | C24H23ClN4O3 | 450.92 | CN(C)C1=CC2=C(C=C1)N=C(N2)C3=C(C=CC(=C3)NC(=O)C4=CC(=CC(=C4)OC)OC)Cl |
| EOS-AX1175 | HIV-1 integrase inhibitor | 544467-07-4 | C11H9N3O4 | 247.21 | C1=CC(=CC(=C1)CN=[N+]=[N-])C(=CC(=O)C(=O)O)O |
| EOS-AX1176 | HIV-1 integrase inhibitor 2 | 957890-42-5 | C21H20ClNO2 | 353.84 | CCCC(C1=C(N=C2C=CC(=CC2=C1C3=CC=CC=C3)Cl)C)C(=O)O |
| EOS-AX1177 | HOE 32020 | 23554-99-6 | C25H23ClN6 | 442.94 | CN1CCN(C2=CC3=C(N=C(C4=CC5=C(N=C(C6=CC=C(Cl)C=C6)N5)C=C4)N3)C=C2)CC1 |
| EOS-AX1178 | HOE 32021 | 23623-06-5 | C26H26N6O | 438.52 | CN1CCN(CC1)C2=CC3=C(C=C2)N=C(N3)C4=CC5=C(C=C4)N=C(N5)C6=CC=C(C=C6)OC |
| EOS-AX1179 | HOE 33187 | 23623-08-7 | C25H24N6 | 408.5 | CN1CCN(C2=CC3=C(N=C(C4=CC5=C(N=C(C6=CC=CC=C6)N5)C=C4)N3)C=C2)CC1 |
| EOS-AX1180 | Hoechst 33258 | 23491-45-4 | C25H27Cl3N6O | 424.5 | CN1CCN(CC1)C2=CC3=C(C=C2)N=C(N3)C4=CC5=C(C=C4)N/C(N5)=C6C=CC(C=C/6)=O.Cl.Cl.Cl |
| EOS-AX1181 | Hoechst 33258 analog | 258843-62-8 | C29H30N6O3 | 510.59 | CN1CCN(C2=CC3=C(N=C(C4=CC5=C(N=C(C6=CC(OCCCC(O)=O)=CC=C6)N5)C=C4)N3)C=C2)CC1 |
| EOS-AX1182 | Hoechst 33258 analog 2 | 23491-54-5 | C26H26N6 | 422.52 | CC1=CC=CC(C2=NC3=C(C=C(C4=NC5=C(C=C(N6CCN(C)CC6)C=C5)N4)C=C3)N2)=C1 |
| EOS-AX1183 | Hoechst 33258 analog 3 | 23554-98-5 | C26H26N6 | 422.52 | CC1=CC=C(C2=NC3=C(N2)C=CC(C4=NC5=C(N4)C=C(N6CCN(CC6)C)C=C5)=C3)C=C1 |
| EOS-AX1184 | Hoechst 33258 analog 5 | 23491-55-6 | C29H26N6 | 458.56 | CN1CCN(C2=CC3=C(N=C(C4=CC5=C(N=C(C6=CC7=CC=CC=C7C=C6)N5)C=C4)N3)C=C2)CC1 |
| EOS-AX1185 | Hoechst 33258 analog 6 | 129244-66-2 | C33H40N6O | 536.71 | CC(C)(C1=C/C(C=C(C(C)(C)C)C1=O)=C2NC3=C(C=C(C4=NC5=C(C=C(N6CCN(C)CC6)C=C5)N4)C=C3)N\2)C |
| EOS-AX1186 | Hoechst 33342 | 23491-52-3 | C27H28N6O | 452.55 | CCOC1=CC=C(C2=NC3=C(C=C(C4=NC5=C(C=C(N6CCN(C)CC6)C=C5)N4)C=C3)N2)C=C1 |
| EOS-AX1187 | Hoechst 33342 analog | 178481-68-0 | C32H37Cl2N7 | 590.59 | CN1CCN(C2=CC3=C(N=C(C4=CC5=C(N=C(CCCC6=CC=C(N(CCCl)CCCl)C=C6)N5)C=C4)N3)C=C2)CC1 |
| EOS-AX1188 | Hoechst 33342 analog 2 | 106050-84-4 | C25H23IN6O | 550.39 | CN1CCN(C2=CC3=C(N=C(C4=CC5=C(N/C(N5)=C6C=CC(C(I)=C/6)=O)C=C4)N3)C=C2)CC1 |
| EOS-AX1189 | Hoechst 34580 | 23555-00-2 | C27H29N7 | 451.57 | CN1CCN(C2=CC3=C(N=C(C4=CC5=C(N=C(C6=CC=C(N(C)C)C=C6)N5)C=C4)N3)C=C2)CC1 |
| EOS-AX1190 | HOE-S 785026 | 132869-83-1 | C25H24N6O | 424.5 | CN1CCN(C2=CC3=C(N=C(C4=CC5=C(N=C(C6=CC(O)=CC=C6)N5)C=C4)N3)C=C2)CC1 |
| EOS-AX1191 | HOKU-81 | 58020-43-2 | C12H18ClNO2 | 243.73 | CC(C)(C)NCC(C1=C(C=C(C=C1)O)Cl)O |
| EOS-AX1192 | Hydroxyfasudil | 105628-72-6 | C14H17N3O3S | 307.37 | C1CNCCN(C1)S(=O)(=O)C2=CC=CC3=C2C=CNC3=O |
| EOS-AX1193 | Hydroxyfasudil hydrochloride | 155558-32-0 | C14H18ClN3O3S | 343.83 | C1CNCCN(C1)S(=O)(=O)C2=CC=CC3=C2C=CNC3=O.Cl |
| EOS-AX1194 | I2906 | 331963-29-2 | C25H37N3O4 | 443.58 | CCCCCCCCCCCCC(=O)NNC(=O)C1=C(C2=CC=CC=C2N(C1=O)CC)O |
| EOS-AX1195 | Ibutamoren Mesylate | 159752-10-0 | C28H40N4O8S2 | 624.77 | CC(C)(C(=O)NC(COCC1=CC=CC=C1)C(=O)N2CCC3(CC2)CN(C4=CC=CC=C34)S(=O)(=O)C)N.CS(=O)(=O)O |
| EOS-AX1196 | Icotinib Hydrochloride | 1204313-51-8 | C22H22ClN3O4 | 427.88 | Cl[H].[H]C1=C2C(N=C([H])N=C2N([H])C3=C([H])C([H])=C([H])C(C#C[H])=C3[H])=C([H])C4=C1OC([H])([H])C([H])([H])OC([H])([H])C([H])([H])OC([H])([H])C([H])([H])O4 |
| EOS-AX1197 | IDO inhibitor 1 | 1204669-37-3 | C11H13BrFN7O4S | 438.23 | BrC1=CC(/N=C(NO)\C2=NON=C2NCCNS(=O)(N)=O)=CC=C1F |
| EOS-AX1198 | Iguratimod | 123663-49-0 | C17H14N2O6S | 374.37 | CS(=O)(=O)NC1=C(C=C2C(=C1)OC=C(C2=O)NC=O)OC3=CC=CC=C3 |
| EOS-AX1199 | IKK-2 inhibitor VIII | 406209-26-5 | C21H25ClN4O2 | 400.9 | C1CC1COC2=CC=CC(=O)C2=C3C=C(C(=C(N3)N)C#N)C4CCNCC4.Cl |
| EOS-AX1200 | IKK-3 Inhibitor | 862812-98-4 | C22H19N3O5S2 | 469.53 | COC1=C(OC)C=C2C(N=CN2C3=CC(OCC4=CC=CC=C4S(=O)(C)=O)=C(C#N)S3)=C1 |
| EOS-AX1201 | Imatinib hydrochloride | 862366-25-4 | C29H32ClN7O | 530.06 | CC1C=CC(=CC1NC2=NC=CC(=N2)C3=CN=CC=C3)NC(=O)C4=CC=C(C=C4)CN5CCN(CC5)C.Cl |
| EOS-AX1202 | Impurity B of Calcitriol | 66791-71-7 | C27H44O3 | 416.64 | CC(CCCC(C)(C)O)C1CCC2C1(CCCC2=CC=C3CC(CC(C3=C)O)O)C |
| EOS-AX1203 | Impurity C of Alfacalcidol | 82266-85-1 | C35H49N3O4 | 575.78 | |
| EOS-AX1204 | Impurity C of Calcitriol | 86307-44-0 | C35H49N3O5 | 591.78 | |
| EOS-AX1205 | Impurity of Calcipotriol | 910133-69-6 | C39H68O3Si2 | 641.13 | |
| EOS-AX1206 | INCB 3284 dimesylate | 887401-93-6 | C28H39F3N4O10S2 | 712.76 | COC1=NC=C(C2(O)CCC(N3CCC(NC(CNC(C4=CC(C(F)(F)F)=CC=C4)=O)=O)C3)CC2)C=C1.CS(=O)(O)=O.CS(=O)(O)=O |
| EOS-AX1207 | INCB024360 analogue | 914471-09-3 | C9H7ClFN5O2 | 271.64 | C1=CC(=C(C=C1NC(=C2C(=NON2)N)N=O)Cl)F |
| EOS-AX1208 | INCB3344 | 1262238-11-8 | C29H34F3N3O6 | 577.24 | CCOC1CN(CC1NC(=O)CNC(=O)C2=CC(=CC=C2)C(F)(F)F)C3CCC(CC3)(C4=CC5=C(C=C4)OCO5)O |
| EOS-AX1209 | INCB8761(PF-4136309) | 1341224-83-6 | C29H31F3N6O3 | 568.59 | O=C(CNC(C1=CC(C(F)(F)F)=CC=C1)=O)N(C2)CCC2NC3CCC(C4=NC=C(C5=NC=CC=N5)C=C4)(O)CC3 |
| EOS-AX1210 | Indacaterol | 312753-06-3 | C24H28N2O3 | 392.49 | CCC1=C(C=C2CC(CC2=C1)NCC(C3=C4C=CC(=O)NC4=C(C=C3)O)O)CC |
| EOS-AX1211 | INNO-206 | 1361644-26-9 | C37H42N4O13 | 750.75 | |
| EOS-AX1212 | Inolitazone | 223132-37-4 | C27H26N4O4S | 502.58 | CC1=CC(OC2=CC3=C(N=C(COC4=CC=C(CC5C(NC(S5)=O)=O)C=C4)N3C)C=C2)=CC(C)=C1N |
| EOS-AX1213 | Inolitazone dihydrochloride | 223132-38-5 | C27H28Cl2N4O4S | 575.51 | Cl[H].Cl[H].O=C1N([H])C(SC1([H])C([H])([H])C(C([H])=C2[H])=C([H])C([H])=C2OC([H])([H])C3=NC(C([H])=C4[H])=C(C([H])=C4OC5=C([H])C(C([H])([H])[H])=C(C(C([H])([H])[H])=C5[H])N([H])[H])N3C([H])([H])[H])=O |
| EOS-AX1214 | IRAK inhibitor 1 | 1042224-63-4 | C17H19N5 | 293.37 | C1CNCCC1NC2=CC=CC(=N2)C3=CN=C4N3C=CC=C4 |
| EOS-AX1215 | IRAK inhibitor 2 | 928333-30-6 | C17H14N4O2 | 306.32 | C1=COC(=C1)CNC2=CC=C3N=CC(=C4C=CC(=O)C=C4)N3N2 |
| EOS-AX1216 | IRAK inhibitor 3 | 1012343-93-9 | C21H21N5O4S | 439.49 | COC1=C(C=C(C=C1)C2=CN=C3N2N=C(C=C3)NCC4=CC=C(C=C4)S(=O)(=O)N)OC |
| EOS-AX1217 | IRAK inhibitor 4 | 1012104-68-5 | C33H35F3N6O3 | 620.66 | CC(C)CCNC(=O)C1=CC2=C(C=C1)N(C(=N2)NC3=NNC4=C3C=C(C=C4)C5=CC=CC=C5OC(F)(F)F)C6CCC(CC6)O |
| EOS-AX1218 | IRAK inhibitor 6 | 1042672-97-8 | C20H20N4O3S | 396.46 | COC1=C(C=CC(=C1)N2CCOCC2)NC(=O)C3=CSC(=N3)C4=CN=CC=C4 |
| EOS-AX1219 | IRAK-1-4 Inhibitor I | 509093-47-4 | C20H21N5O4 | 395.41 | C1COCCN1CCN2C3=CC=CC=C3N=C2NC(=O)C4=CC(=CC=C4)[N+](=O)[O-] |
| EOS-AX1220 | Isobavachalcone | 20784-50-3 | C20H20O4 | 324.38 | CC(=CCC1=C(C=CC(=C1O)C(=O)C=CC2=CC=C(C=C2)O)O)C |
| EOS-AX1221 | Istaroxime | 203737-93-3 | C21H32N2O3 | 360.49 | CC12CC/C(CC1C(CC3C2CCC4(C)C3CCC4=O)=O)=N\OCCN |
| EOS-AX1222 | Istaroxime hydrochloride | 374559-48-5 | C21H33ClN2O3 | 396.95 | CC12CCC(=NOCCN)CC1C(=O)CC3C2CCC4(C3CCC4=O)C.Cl |
| EOS-AX1223 | ITK inhibitor | 439574-61-5 | C31H39N5O4S2 | 609.82 | CC1=C(C=C(C(=C1)OC)C(=O)N2CCN(CC2)C(=O)C)SC3=CN=C(S3)NC(=O)C4=CC=C(C=C4)CNC(C)C(C)C |
| EOS-AX1224 | Ivacaftor benzenesulfonate | 1134822-09-5 | C30H34N2O6S | 550.67 | CC(C)(C1=CC(C(C)(C)C)=C(O)C=C1/N=C(O)/C2=CNC3=CC=CC=C3C2=O)C.OS(C4=CC=CC=C4)(=O)=O |
| EOS-AX1225 | Ivacaftor hydrate | 1134822-07-3 | C24H30N2O4 | 410.51 | CC(C)(C1=CC(C(C)(C)C)=C(O)C=C1/N=C(O)/C2=CNC3=CC=CC=C3C2=O)C.O |
| EOS-AX1226 | IWP-2 | 686770-61-6 | C22H18N4O2S3 | 466.6 | CC1=CC2=C(C=C1)N=C(S2)NC(=O)CSC3=NC4=C(C(=O)N3C5=CC=CC=C5)SCC4 |
| EOS-AX1227 | Ixabepilone | 219989-84-1 | C27H42N2O5S | 506.7 | CC1CCCC2(C(O2)CC(NC(=O)CC(C(C(=O)C(C1O)C)(C)C)O)C(=CC3=CSC(=N3)C)C)C |
| EOS-AX1228 | JAK2 Inhibitor V, Z3 | 195371-52-9 | C23H24N2O | 344.45 | CC(CCC1=CC=CC=N1)(C(C2=CC=CC=C2)=O)CCC3=CC=CC=N3 |
| EOS-AX1229 | JANEX-1 | 202475-60-3 | C16H15N3O3 | 297.31 | COC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=C(C=C3)O)OC |
| EOS-AX1230 | JC-1 | 3520-43-2 | C25H27Cl4IN4 | 652.23 | CCN1C2=CC(=C(C=C2[N+](=C1C=CC=C3N(C4=CC(=C(C=C4N3CC)Cl)Cl)CC)CC)Cl)Cl.[I-] |
| EOS-AX1231 | JDTic | 361444-66-8 | C28H39N3O3 | 465.63 | CC1CN(CC(NC(C2CC3=C(C=C(O)C=C3)CN2)=O)C(C)C)CCC1(C4=CC(O)=CC=C4)C |
| EOS-AX1232 | JDTic 2HCl | 785835-79-2 | C28H41Cl2N3O3 | 538.55 | CC1CN(CCC1(C)C2=CC(=CC=C2)O)CC(C(C)C)NC(=O)C3CC4=C(CN3)C=C(C=C4)O.Cl.Cl |
| EOS-AX1233 | JNK-IN-7 | 1408064-71-0 | C28H27N7O2 | 493.56 | CN(C)CC=CC(=O)NC1=CC=CC(=C1)C(=O)NC2=CC=C(C=C2)NC3=NC=CC(=N3)C4=CN=CC=C4 |
| EOS-AX1234 | JNK-IN-8 | 1410880-22-6 | C29H29N7O2 | 507.59 | CC1=C(C=CC(=C1)NC(=O)C2=CC(=CC=C2)NC(=O)C=CCN(C)C)NC3=NC=CC(=N3)C4=CN=CC=C4 |
| EOS-AX1235 | JWH 073 | 208987-48-8 | C23H21NO | 327.42 | |
| EOS-AX1236 | Kaempferide | 491-54-3 | C16H12O6 | 300.26 | COC1=CC=C(C=C1)C2=C(C(=O)C3=C(C=C(C=C3O2)O)O)O |
| EOS-AX1237 | Kaempferol | 520-18-3 | C15H10O6 | 286.24 | O=C(C1=C(O)C=C(O)C=C1O2)C(O)=C2C3=CC=C(O)C=C3 |
| EOS-AX1238 | kb NB 142-70 | 1233533-04-4 | C11H9NO2S2 | 251.32 | C1CSC2=C(C(=O)N1)SC3=C2C=C(C=C3)O |
| EOS-AX1239 | KB-R7943 mesylate | 182004-65-5 | C17H21N3O6S2 | 427.5 | CS(=O)(=O)O.C1=CC(=CC=C1CCSC(=N)N)OCC2=CC=C(C=C2)[N+](=O)[O-] |
| EOS-AX1240 | Ketone Ester | 1208313-97-6 | C8H16O4 | 176.21 | CC(CCOC(=O)CC(C)O)O |
| EOS-AX1241 | Ki20227 | 623142-96-1 | C24H24N4O5S | 480.55 | CC(C1=NC=CS1)NC(=O)NC2=C(C=C(C=C2)OC3=C4C=C(C(=CC4=NC=C3)OC)OC)OC |
| EOS-AX1242 | Kinetin | 525-79-1 | C10H9N5O | 215.21 | C1=COC(=C1)CNC2=NC=NC3=C2NC=N3 |
| EOS-AX1243 | KN-92 | 176708-42-2 | C24H25ClN2O3S | 456.98 | CN(CC1=CC=CC=C1NS(=O)(C2=CC=C(OC)C=C2)=O)C/C=C/C3=CC=C(Cl)C=C3 |
| EOS-AX1244 | KN-92 hydrochloride | 1431698-47-3 | C24H26Cl2N2O3S | 493.45 | ClC1=CC=C(/C=C/CN(C)CC2=CC=CC=C2NS(C3=CC=C(OC)C=C3)(=O)=O)C=C1.Cl |
| EOS-AX1245 | KN-92 phosphate | 1135280-28-2 | C24H28ClN2O7PS | 554.98 | CN(CC1=CC=CC=C1NS(C2=CC=C(OC)C=C2)(=O)=O)C/C([H])=C([H])/C3=CC=C(Cl)C=C3.OP(O)(O)=O |
| EOS-AX1246 | KN-93 | 139298-40-1 | C26H29ClN2O4S | 501.04 | CN(CC=CC1=CC=C(C=C1)Cl)CC2=CC=CC=C2N(CCO)S(=O)(=O)C3=CC=C(C=C3)OC |
| EOS-AX1247 | Ko 143 | 461054-93-3 | C26H35N3O5 | 469.59 | O=C1N2[C@@H](CC(C)C)C(NC3=C4C=CC(OC)=C3)=C4C[C@@H]2C(N[C@@H]1CCC(OC(C)(C)C)=O)=O |
| EOS-AX1248 | KU14R | 189224-48-4 | C13H14N2O | 214.26 | CCC1(C2=NC=CN2)CC3=CC=CC=C3O1 |
| EOS-AX1249 | KX2-391 dihydrochloride | 1038395-65-1 | C26H31Cl2N3O3 | 504.45 | C1COCCN1CCOC2=CC=C(C=C2)C3=CN=C(C=C3)CC(=O)NCC4=CC=CC=C4.Cl.Cl |
| EOS-AX1250 | L-165041 | 79558-09-1 | C22H26O7 | 402.44 | CCCC1=C(C=CC(=C1O)C(=O)C)OCCCOC2=CC=C(C=C2)OCC(=O)O |
| EOS-AX1251 | Lacosamide | 175481-36-4 | C13H18N2O3 | 250.29 | |
| EOS-AX1252 | Laropiprant | 571170-77-9 | C21H19ClFNO4S | 435.9 | CS(=O)(=O)C1=C2C(=CC(=C1)F)C3=C(N2CC4=CC=C(C=C4)Cl)C(CC3)CC(=O)O |
| EOS-AX1253 | Lck Inhibitor | 847950-09-8 | C31H30N8O | 530.62 | O=C1N(C2=C(C([H])([H])[H])C([H])=C([H])C([H])=C2C([H])([H])[H])C3=NC4=C([H])C([H])=C([H])C([H])=C4N3C5=NC(N([H])C6=C([H])C([H])=C(C([H])=C6[H])N7C([H])([H])C([H])([H])N(C([H])([H])[H])C([H])([H])C7([H])[H])=NC([H])=C51 |
| EOS-AX1254 | Lck inhibitor 2 | 944795-06-6 | C18H17N5O2 | 335.36 | CC1=C(C=C(C=C1)O)NC2=NC(=NC=C2)NC3=CC=CC(=C3)C(=O)N |
| EOS-AX1255 | LCL161 | 1005342-46-0 | C26H33FN4O3S | 500.63 | CC(C(=O)NC(C1CCCCC1)C(=O)N2CCCC2C3=NC(=CS3)C(=O)C4=CC=C(C=C4)F)NC |
| EOS-AX1256 | LCQ-908 | 956136-95-1 | C25H24F3N3O2 | 455.47 | C1CC(CCC1CC(=O)O)C2=CC=C(C=C2)C3=NC=C(C=C3)NC4=CN=C(C=C4)C(F)(F)F |
| EOS-AX1257 | LDE225 Diphosphate | 1218778-77-8 | C26H32F3N3O11P2 | 681.49 | CC1CN(CC(O1)C)C2=NC=C(C=C2)NC(=O)C3=CC=CC(=C3C)C4=CC=C(C=C4)OC(F)(F)F.OP(=O)(O)O.OP(=O)(O)O |
| EOS-AX1258 | LDK378 dihydrochloride | 1380575-43-8 | C28H38Cl3N5O3S | 631.06 | CC1=CC(=C(C=C1C2CCNCC2)OC(C)C)NC3=NC=C(C(=N3)NC4=CC=CC=C4S(=O)(=O)C(C)C)Cl.Cl.Cl |
| EOS-AX1259 | LDN193189 Hydrochloride | 1062368-62-0 | C25H26Cl4N6 | 552.33 | C1CN(CCN1)C2=CC=C(C=C2)C3=CN4C(=C(C=N4)C5=CC=NC6=CC=CC=C56)N=C3.Cl.Cl.Cl.Cl |
| EOS-AX1260 | Ledipasvir | 1256388-51-8 | C49H54F2N8O6 | 889 | CC([C@@](/N=C(OC)\O)([H])C(N1CC2(C[C@@]1([H])C3=NC=C(N3)C4=CC5=C(C6=C(C5(F)F)C=C(C7=CC(N8)=C(N=C8[C@]9([H])[C@@]%10([H])CC[C@](N9C([C@](/N=C(OC)\O)([H])C(C)C)=O)([H])C%10)C=C7)C=C6)C=C4)CC2)=O)C |
| EOS-AX1261 | Lenalidomide hydrochloride | 1243329-97-6 | C13H14ClN3O3 | 295.72 | O=C1N(C2C(NC(CC2)=O)=O)CC3=C(N)C=CC=C31.Cl |
| EOS-AX1262 | Lersivirine | 473921-12-9 | C17H18N4O2 | 310.35 | CCC1=C(C(=NN1CCO)CC)OC2=CC(=CC(=C2)C#N)C#N |
| EOS-AX1263 | Lesinurad | 878672-00-5 | C17H14BrN3O2S | 404.28 | C1CC1C2=CC=C(C3=CC=CC=C23)N4C(=NN=C4Br)SCC(=O)O |
| EOS-AX1264 | Letermovir | 917389-32-3 | C29H28F4N4O4 | 572.55 | COC1=C(C=C(C=C1)C(F)(F)F)N2C(C3=C(C(=CC=C3)F)N=C2N4CCN(CC4)C5=CC(=CC=C5)OC)CC(=O)O |
| EOS-AX1265 | Leuprolide Acetate | 74381-53-6 | C61H88N16O14 | 1269.45 | CCNC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CC5=CN=CN5)NC(=O)C6CCC(=O)N6.CC(=O)O |
| EOS-AX1266 | Levomefolate calcium | 151533-22-1 | C40H48CaN14O12 | 499.53 | CN1C(CNC2=C1C(=O)N=C(N2)N)CNC3=CC=C(C=C3)C(=O)NC(CCC(=O)O)C(=O)O.[Ca+2] |
| EOS-AX1267 | Levomefolic acid | 31690-09-2 | C20H25N7O6 | 459.46 | CN1C(CNC2=CC=C(C(NC(C(O)=O)CCC(O)=O)=O)C=C2)CNC3=C1C(N=C(N)N3)=O |
| EOS-AX1268 | Lexacalcitol | 131875-08-6 | C29H48O4 | 460.69 | CCC(CC)(CCCOC(C)C1CCC2C1(CCCC2=CC=C3CC(CC(C3=C)O)O)C)O |
| EOS-AX1269 | Limonin | 1180-71-8 | C26H30O8 | 470.51 | CC1(C2CC(=O)C3(C(C24COC(=O)CC4O1)CCC5(C36C(O6)C(=O)OC5C7=COC=C7)C)C)C |
| EOS-AX1270 | LKB1 (AAK1 dual inhibitor) | 1093222-27-5 | C20H13N5O | 339.36 | C1=CC(=CN=C1)C(=O)NC2=CNC3=NC=C(C=C23)C4=CC=C(C=C4)C#N |
| EOS-AX1271 | Lorcaserin | 616202-92-7 | C11H14ClN | 195.69 | |
| EOS-AX1272 | LRRK2-IN-1 | 1234480-84-2 | C31H38N8O3 | 570.7 | CN1CCN(CC1)C2CCN(CC2)C(=O)C3=CC(=C(C=C3)NC4=NC=C5C(=N4)N(C6=CC=CC=C6C(=O)N5C)C)OC |
| EOS-AX1273 | L-Stepholidine | 16562-13-3 | C19H21NO4 | 327.37 | COC1=C(O)C=C2C3CC4=C(C(OC)=C(O)C=C4)CN3CCC2=C1 |
| EOS-AX1274 | Lu AE58054 | 467459-31-0 | C20H19F5N2O | 398.37 | C1=CC(=CC(=C1)OCC(C(F)F)(F)F)CNCCC2=CNC3=C2C=CC(=C3)F |
| EOS-AX1275 | Lu AE58054 Hydrochloride | 467458-02-2 | C20H20ClF5N2O | 434.83 | C1=CC(=CC(=C1)OCC(C(F)F)(F)F)CNCCC2=CNC3=C2C=CC(=C3)F.Cl |
| EOS-AX1276 | Lucidin | 478-08-0 | C15H10O5 | 270.24 | C1=CC=C2C(=C1)C(=O)C3=CC(=C(C(=C3C2=O)O)CO)O |
| EOS-AX1277 | LUF6000 | 890087-21-5 | C22H20Cl2N4 | 411.33 | C1CCC(CC1)C2=NC3=C(N2)C(=NC4=CC=CC=C43)NC5=CC(=C(C=C5)Cl)Cl |
| EOS-AX1278 | Luliconazole | 187164-19-8 | C14H9Cl2N3S2 | 354.28 | C1C(SC(=C(C#N)N2C=CN=C2)S1)C3=C(C=C(C=C3)Cl)Cl |
| EOS-AX1279 | LX-1031 | 945976-76-1 | C28H25F3N4O4 | 538.52 | COC1=CC=CC(=C1)C2=CC=C(C=C2)C(C(F)(F)F)OC3=NC(=NC(=C3)C4=CC=C(C=C4)CC(C(=O)O)N)N |
| EOS-AX1280 | LX1606 | 1137608-69-5 | C36H35ClF3N7O6 | 754.17 | CCOC(=O)C(CC1=CC=C(C=C1)C2=CC(=NC(=N2)N)OC(C3=C(C=C(C=C3)Cl)N4C=CC(=N4)C)C(F)(F)F)N.C1=CC=C(C=C1)C(=O)NCC(=O)O |
| EOS-AX1281 | LX-4211 | 1018899-04-1 | C21H25ClO5S | 424.94 | CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)C3C(C(C(C(O3)SC)O)O)O)Cl |
| EOS-AX1282 | LY 303511 | 154447-38-8 | C19H18N2O2 | 306.36 | O=C(C1=CC=CC(C2=CC=CC=C2)=C1O3)C=C3N4CCNCC4 |
| EOS-AX1283 | LY 344864 | 186544-26-3 | C21H22FN3O | 351.42 | CN([C@]1([H])CCC2=C(C3=C(N2)C=CC(NC(C4=CC=C(F)C=C4)=O)=C3)C1)C |
| EOS-AX1284 | LY2090314 | 603288-22-8 | C28H25FN6O3 | 512.53 | FC1=C([H])C2=C(C(C(C(C(N([H])C3=O)=O)=C3C4=C([H])N=C5N4C([H])=C([H])C([H])=C5[H])=C6[H])=C1[H])N6C([H])([H])C([H])([H])N(C(N7C([H])([H])C([H])([H])C([H])([H])C([H])([H])C7([H])[H])=O)C2([H])[H] |
| EOS-AX1285 | LY2183240 | 874902-19-9 | C17H17N5O | 307.35 | CN(C)C(=O)N1C(=NN=N1)CC2=CC=C(C=C2)C3=CC=CC=C3 |
| EOS-AX1286 | LY2795050 | 1346133-08-1 | C23H22ClN3O2 | 407.89 | O=C(N)C(C=C1)=CC(Cl)=C1OC(C=C2)=CC=C2CN3C(C4=CN=CC=C4)CCC3 |
| EOS-AX1287 | LY2801653 | 1206799-15-6 | C30H22F2N6O3 | 552.53 | CC1=CC=C(C(=O)N1C2=CC=C(C=C2)F)C(=O)NC3=CC(=C(C=C3)OC4=C(C=C5C(=C4)C=NN5C)C6=CNN=C6)F |
| EOS-AX1288 | LY2801653 dihydrochloride | 1206801-37-7 | C30H24Cl2F2N6O3 | 625.45 | CC1=CC=C(C(=O)N1C2=CC=C(C=C2)F)C(=O)NC3=CC(=C(C=C3)OC4=C(C=C5C(=C4)C=NN5C)C6=CNN=C6)F.Cl.Cl |
| EOS-AX1289 | LY2835219 free base | 1231929-97-7 | C27H32F2N8 | 506.59 | CCN1CCN(CC2=CN=C(NC3=NC=C(F)C(C4=CC5=C(N=C(C)N5C(C)C)C(F)=C4)=N3)C=C2)CC1 |
| EOS-AX1290 | LY2874455 | 1254473-64-7 | C21H19Cl2N5O2 | 444.31 | CC(C1=C(C=NC=C1Cl)Cl)OC2=CC3=C(C=C2)NN=C3C=CC4=CN(N=C4)CCO |
| EOS-AX1291 | LY341495 | 201943-63-7 | C20H19NO5 | 353.38 | C1C(C1C(CC2C3=CC=CC=C3OC4=CC=CC=C24)(C(=O)O)N)C(=O)O |
| EOS-AX1292 | LY450108 | 376594-67-1 | C19H22F2N2O3S | 396.45 | CC(S(=O)(NCC(C1=CC=C(NC(C2=CC(F)=CC(F)=C2)=O)C=C1)C)=O)C |
| EOS-AX1293 | M2 ion channel blocker | 1190215-03-2 | C19H29N3O2 | 331.45 | CC(C12CC3CC(C1)CC(C3)C2)NC(CC4C=NC=N4)C(=O)OC |
| EOS-AX1294 | MAC13243 | 1071638-38-4 | C20H25Cl2N3O2S | 442.4 | COC1=C(C=C(C=C1)CCN2CNC(=NC2)SCC3=CC=C(C=C3)Cl)OC.Cl |
| EOS-AX1295 | Maropitant | 147116-67-4 | C32H40N2O | 468.67 | CC(C)(C1=CC(CNC2C3CCN(CC3)C2C(C4=CC=CC=C4)C5=CC=CC=C5)=C(OC)C=C1)C |
| EOS-AX1296 | Masitinib mesylate | 1048007-93-7 | C29H34N6O4S2 | 594.75 | CC1=C(NC2=NC(C3=CN=CC=C3)=CS2)C=C(NC(C4=CC=C(CN5CCN(C)CC5)C=C4)=O)C=C1.CS(=O)(O)=O |
| EOS-AX1297 | Matrine | 519-02-8 | C15H24N2O | 248.36 | O=C1N(C[C@@]2([H])[C@@]3([H])[C@]4([H])CCCN3CCC2)[C@]4([H])CCC1 |
| EOS-AX1298 | Maxacalcitol | 103909-75-7 | C26H42O4 | 418.62 | CC(C1CCC2C1(CCCC2=CC=C3CC(CC(C3=C)O)O)C)OCCC(C)(C)O |
| EOS-AX1299 | Mazindol | 22232-71-9 | C16H13ClN2O | 284.74 | |
| EOS-AX1300 | MB05032 | 261365-11-1 | C11H15N2O4PS | 302.29 | NC1=NC(C2=CC=C(P(O)(O)=O)O2)=C(CC(C)C)S1 |
| EOS-AX1301 | MBX-2982 | 1037792-44-1 | C22H24N8OS | 448.54 | CCC1=CN=C(N=C1)N2CCC(CC2)C3=NC(=CS3)COC4=CC=C(C=C4)N5C=NN=N5 |
| EOS-AX1302 | MC 1046 | 126860-83-1 | C27H38O3 | 410.59 | CC(C=CC(=O)C1CC1)C2CCC3C2(CCCC3=CC=C4CC(CC(C4=C)O)O)C |
| EOS-AX1303 | MC 976 | 129831-99-8 | C27H42O3 | 414.62 | CC(CCC(C1CC1)O)C2CCC3C2(CCCC3=CC=C4CC(CC(C4=C)O)O)C |
| EOS-AX1304 | Mc-MMAD | 1401963-15-2 | C51H77N7O9S | 964.26 | CC[C@]([C@@](N(C([C@](/N=C(O)/[C@](N(C(CCCCCN1C(C=CC1=O)=O)=O)C)([H])C(C)C)([H])C(C)C)=O)C)([H])[C@@](OC)([H])CC(N2CCC[C@@]2([H])[C@@](OC)([H])[C@@](/C(O)=N/[C@@](C3=NC=CS3)([H])CC4=CC=CC=C4)([H])C)=O)([H])C |
| EOS-AX1305 | MDA 19 | 1048973-47-2 | C21H23N3O2 | 349.43 | |
| EOS-AX1306 | Medetomidine | 86347-14-0 | C13H16N2 | 200.28 | CC1=C(C)C(C(C2=CN=CN2)C)=CC=C1 |
| EOS-AX1307 | Mefloquine hydrochloride | 51773-92-3 | C17H17ClF6N2O | 414.77 | C1CCNC(C1)C(C2=CC(=NC3=C2C=CC=C3C(F)(F)F)C(F)(F)F)O.Cl |
| EOS-AX1308 | MEK inhibitor | 334951-92-7 | C26H26N4O2 | 426.51 | CNC(=O)C1=CC2=C(C=C1)C(=C(C3=CC=CC=C3)NC4=CC=CC(=C4)CN(C)C)C(=O)N2 |
| EOS-AX1309 | meta-iodoHoechst 33258 | 158013-42-4 | C25H23IN6 | 534.39 | CN1CCN(C2=CC3=C(N=C(C4=CC5=C(N=C(C6=CC(I)=CC=C6)N5)C=C4)N3)C=C2)CC1 |
| EOS-AX1310 | Methylnaltrexone Bromide | 73232-52-7 | C21H26BrNO4 | 436.34 | C[N+]1(CCC23C4C(=O)CCC2(C1CC5=C3C(=C(C=C5)O)O4)O)CC6CC6.[Br-] |
| EOS-AX1311 | Methylproamine | 188247-01-0 | C28H31N7 | 465.59 | CC1=C(C2=NC3=C(C=C(C4=NC5=C(C=C(N6CCN(C)CC6)C=C5)N4)C=C3)N2)C=CC(N(C)C)=C1 |
| EOS-AX1312 | Metiamide | 34839-70-8 | C9H16N4S2 | 244.38 | CC1=C(N=CN1)CSCCNC(=S)NC |
| EOS-AX1313 | Metoclopramide | 364-62-5 | C14H22ClN3O2 | 299.8 | CCN(CC)CCNC(=O)C1=CC(=C(C=C1OC)N)Cl |
| EOS-AX1314 | MF63 | 892549-43-8 | C23H11ClN4 | 378.81 | ClC1=CC(C2=CC=CC=C2C3=C4NC(C5=C(C#N)C=CC=C5C#N)=N3)=C4C=C1 |
| EOS-AX1315 | mGlu2 agonist | 1311385-32-6 | C13H22N6O6S | 390.42 | CC(C(=O)NC1(CC(C2C1C2C(=O)O)SC3=NC=NN3)C(=O)O)N.N.O |
| EOS-AX1316 | MI-2 | 1271738-62-5 | C18H25N5S2 | 375.55 | CCCC1=CC2=C(N=CN=C2S1)N3CCN(CC3)C4=NCC(S4)(C)C |
| EOS-AX1317 | MI-3 | 1271738-59-0 | C18H25N5S2 | 375.55 | CC(C1=CC2=C(N3CCN(C(S4)=NCC4(C)C)CC3)N=CN=C2S1)C |
| EOS-AX1318 | Mibefradil | 116644-53-2 | C29H38FN3O3 | 495.63 | CC(C1C2=C(C=C(F)C=C2)CCC1(OC(COC)=O)CCN(CCCC3=NC4=CC=CC=C4N3)C)C |
| EOS-AX1319 | Mibefradil dihydrochloride | 116666-63-8 | C29H40Cl2FN3O3 | 568.55 | CC(C)C1C2=C(CCC1(CCN(C)CCCC3=NC4=CC=CC=C4N3)OC(=O)COC)C=C(C=C2)F.Cl.Cl |
| EOS-AX1320 | Micafungin sodium | 208538-73-2 | C56H70N9NaO23S | 1292.26 | CCCCCOC1=CC=C(C=C1)C2=CC(=NO2)C3=CC=C(C=C3)C(=O)NC4CC(C(NC(=O)C5C(C(CN5C(=O)C(NC(=O)C(NC(=O)C6CC(CN6C(=O)C(NC4=O)C(C)O)O)C(C(C7=CC(=C(C=C7)O)OS(=O)(=O)[O-])O)O)C(CC(=O)N)O)C)O)O)O.[Na+] |
| EOS-AX1321 | Miriplatin hydrate | 250159-48-9 | C34H70N2O5Pt | 782.01 | CCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCC([O-])=O.N[C@]1([H])CCCC[C@@]1([H])N.O.[Pt+2] |
| EOS-AX1322 | MK 0893 | 870823-12-4 | C32H27Cl2N3O4 | 587.14 | CC(C1=CC=C(C=C1)C(=O)NCCC(=O)O)N2C(=CC(=N2)C3=CC(=CC(=C3)Cl)Cl)C4=CC5=C(C=C4)C=C(C=C5)OC |
| EOS-AX1323 | MK-0591 | 136668-42-3 | C34H35ClN2O3S | 587.17 | CC(C)(C)SC1=C(N(C2=C1C=C(C=C2)OCC3=NC4=CC=CC=C4C=C3)CC5=CC=C(C=C5)Cl)CC(C)(C)C(=O)O |
| EOS-AX1324 | MK-0773 | 606101-58-0 | C27H34FN5O2 | 479.59 | CC12CCC3C(C1CCC2C(=O)NCC4=NC5=C(N4)C=CC=N5)CCC6C3(C=C(C(=O)N6C)F)C |
| EOS-AX1325 | MK-0812 | 624733-88-6 | C24H34F3N3O3 | 469.54 | CC(C1(C(N2CCC3=NC=C(C(F)(F)F)C=C3C2)=O)CCC(NC4CCOCC4OC)C1)C |
| EOS-AX1326 | MK-0974 | 781649-09-0 | C26H27F5N6O3 | 566.54 | C1CC(C(=O)N(CC1C2=C(C(=CC=C2)F)F)CC(F)(F)F)NC(=O)N3CCC(CC3)N4C5=C(NC4=O)N=CC=C5 |
| EOS-AX1327 | MK-2894 | 1006036-87-8 | C25H22F3NO3S | 473.51 | CC1=C(C(=C(S1)C)C(=O)NC2(CC2)C3=CC=C(C=C3)C(=O)O)CC4=CC=C(C=C4)C(F)(F)F |
| EOS-AX1328 | MK-2894 sodium salt | 1006036-88-9 | C25H21F3NNaO3S | 495.49 | CC1=C(CC2=CC=C(C(F)(F)F)C=C2)C(C(NC3(C4=CC=C(C([O-])=O)C=C4)CC3)=O)=C(C)S1.[Na+] |
| EOS-AX1329 | MK-3207 | 957118-49-9 | C31H29F2N5O3 | 557.59 | C1CCC2(C1)C(=O)N(C(CN2)C3=CC(=CC(=C3)F)F)CC(=O)NC4=CC5=C(CC6(C5)C7=C(NC6=O)N=CC=C7)C=C4 |
| EOS-AX1330 | MK-4305 | 1030377-33-3 | C23H23ClN6O2 | 450.92 | |
| EOS-AX1331 | MK-4827 | 1038915-60-4 | C19H20N4O | 320.39 | C1CC(CNC1)C2=CC=C(C=C2)N3C=C4C=CC=C(C4=N3)C(=O)N |
| EOS-AX1332 | MK-5172 | 1350514-68-9 | C38H50N6O9S | 766.9 | COC1=CC2=C(N=C(CCCCC[C@@H]3C[C@H]3OC(N[C@@H](C(C)(C)C)C(N4[C@H](C(N[C@@]5(C(NS(=O)(C6CC6)=O)=O)[C@H](C5)C=C)=O)C[C@@H]7C4)=O)=O)C(O7)=N2)C=C1 |
| EOS-AX1333 | MK-5172 hydrate | 1350462-55-3 | C38H52N6O10S | 784.92 | CC(C)(C1C(N2CC(OC3=NC4=C(N=C3CCCCCC5CC5OC(N1)=O)C=CC(OC)=C4)CC2C(NC6(C(NS(=O)(C7CC7)=O)=O)CC6C=C)=O)=O)C.O |
| EOS-AX1334 | MK-5172 potassium salt | 1206524-86-8 | C38H50KN6O9S+ | 806 | COC1=CC2=C(N=C(CCCCC[C@@H]3C[C@H]3OC(N[C@@H](C(C)(C)C)C(N4[C@H](C(N[C@@]5(C(NS(=O)(C6CC6)=O)=O)[C@H](C5)C=C)=O)C[C@@H]7C4)=O)=O)C(O7)=N2)C=C1.[K+] |
| EOS-AX1335 | MK-5172 sodium salt | 1425038-27-2 | C38H50N6NaO9S+ | 789.89 | CC(C)(C1C(N2CC(OC3=NC4=C(N=C3CCCCCC5CC5OC(N1)=O)C=CC(OC)=C4)CC2C(NC6(C(NS(=O)(C7CC7)=O)=O)CC6C=C)=O)=O)C.[Na+] |
| EOS-AX1336 | MK591 | 147030-01-1 | C34H34ClN2NaO3S | 609.15 | CC(C)(C)SC1=C(N(C2=C1C=C(C=C2)OCC3=NC4=CC=CC=C4C=C3)CC5=CC=C(C=C5)Cl)CC(C)(C)C(=O)[O-].[Na+] |
| EOS-AX1337 | MK-6892 | 917910-45-3 | C19H22N4O5 | 386.4 | CC(C)(CC1=NC(=C2C=CC(=O)C=N2)NO1)C(=O)NC3=C(CCCC3)C(=O)O |
| EOS-AX1338 | MK-8033 | 1001917-37-8 | C25H21N5O3S | 471.53 | CN1C=C(C2=CN=C3C=CC4=C(C(C3=C2)=O)C=C(CS(=O)(NCC5=CC=CC=N5)=O)C=C4)C=N1 |
| EOS-AX1339 | MK-8245 Trifluoroacetate | 1415559-41-9 | C19H17BrF4N6O6 | 581.27 | C1CN(CCC1OC2=C(C=CC(=C2)F)Br)C3=NOC(=C3)C4=NN(N=N4)CC(=O)O.C(=O)(C(F)(F)F)O |
| EOS-AX1340 | ML-7 hydrochloride | 110448-33-4 | C15H18ClIN2O2S | 452.74 | IC1=CC=CC2=C1C=CC=C2S(N3CCCNCC3)(=O)=O.Cl |
| EOS-AX1341 | MLN 2480 | 1096708-71-2 | C17H12Cl2F3N7O2S | 506.29 | CC(C1=NC=C(S1)C(=O)NC2=NC=C(C(=C2)C(F)(F)F)Cl)NC(=O)C3=C(C(=NC=N3)N)Cl |
| EOS-AX1342 | MLN120B | 783348-36-7 | C19H15ClN4O2 | 366.8 | CC1=C(C=CC=N1)C(=O)NC2=C3C(=CC(=C2OC)Cl)C4=C(N3)C=NC=C4 |
| EOS-AX1343 | MLN4924 HCl salt | 1160295-21-5 | C21H26ClN5O4S | 479.98 | C1CC2=CC=CC=C2C1NC3=NC=NC4=C3C=CN4C5CC(C(C5)O)COS(=O)(=O)N.Cl |
| EOS-AX1344 | MMAD | 203849-91-6 | C41H66N6O6S | 771.06 | O=C([C@@H]([C@@H](OC)[C@]1([H])CCCN1C(C[C@@H](OC)[C@@H](N(C)C([C@@H](NC([C@H](C(C)C)N([H])C)=O)C(C)C)=O)[C@@H](C)CC)=O)C)N[C@H](C2=NC=CS2)CC3=CC=CC=C3 |
| EOS-AX1345 | Monomethyl auristatin E | 474645-27-7 | C39H67N5O7 | 717.98 | CCC(C)C(C(CC(=O)N1CCCC1C(C(C)C(=O)NC(C)C(C2=CC=CC=C2)O)OC)OC)N(C)C(=O)C(C(C)C)NC(=O)C(C(C)C)NC |
| EOS-AX1346 | Motesanib | 453562-69-1 | C22H23N5O | 373.46 | CC1(CNC2=C1C=CC(=C2)NC(=O)C3=C(N=CC=C3)NCC4=CC=NC=C4)C |
| EOS-AX1347 | MPEP Hydrochloride | 219911-35-0 | C14H12ClN | 229.7 | CC1=CC=CC(=N1)C#CC2=CC=CC=C2.Cl |
| EOS-AX1348 | MPTP hydrochloride | 23007-85-4 | C12H16ClN | 209.72 | CN1CCC(=CC1)C2=CC=CC=C2.Cl |
| EOS-AX1349 | MRT67307 | 1190378-57-4 | C26H36N6O2 | 464.62 | C1CC(C1)C(=O)NCCCNC2=NC(=NC=C2C3CC3)NC4=CC=CC(=C4)CN5CCOCC5 |
| EOS-AX1350 | MTEP hydrochloride | 1186195-60-7 | C11H9ClN2S | 236.72 | CC1=NC(=CS1)C#CC2=CN=CC=C2.Cl |
| EOS-AX1351 | GDC-mTOR inhibitor | 1207358-59-5 | C25H30N8O2 | 474.56 | CCNC(=O)NC1=CC=C(C=C1)C2=NC3=C(CCN(C3)C4=NC=CC=N4)C(=N2)N5CCOCC5C |
| EOS-AX1352 | N3PT | 13860-66-7 | C13H19Cl2N3OS | 336.28 | CC1=NC(=C(C=C1)C[N+]2=CSC(=C2C)CCO)N.Cl.[Cl-] |
| EOS-AX1353 | Naltrexone | 16590-41-3 | C20H23NO4 | 341.4 | |
| EOS-AX1354 | Nandrolone | 434-22-0 | C18H26O2 | 274.4 | |
| EOS-AX1355 | Naphthoquine phosphate | 173531-58-3 | C24H34ClN3O9P2 | 605.94 | CC(C)(C)NCC1=CC(=C2CCCCC2=C1O)NC3=C4C=CC(=CC4=NC=C3)Cl.OP(=O)(O)O.OP(=O)(O)O |
| EOS-AX1356 | Narciclasine | 29477-83-6 | C14H13NO7 | 307.26 | C1OC2=C(O1)C(=C3C(=C2)C4=CC(C(C(C4NC3=O)O)O)O)O |
| EOS-AX1357 | Narlaprevir | 865466-24-6 | C36H61N5O7S | 707.96 | CCCCC(C(=O)C(=O)NC1CC1)NC(=O)C2C3C(C3(C)C)CN2C(=O)C(C(C)(C)C)NC(=O)NC4(CCCCC4)CS(=O)(=O)C(C)(C)C |
| EOS-AX1358 | NB-598 | 131060-14-5 | C27H31NOS2 | 449.67 | CCN(CC1=CC(OCC2=CC(C3=CSC=C3)=CS2)=CC=C1)C/C=C/C#CC(C)(C)C |
| EOS-AX1359 | NB-598 hydrochloride | 136719-25-0 | C27H32ClNOS2 | 486.13 | CCN(CC=CC#CC(C)(C)C)CC1=CC(=CC=C1)OCC2=CC(=CS2)C3=CSC=C3.Cl |
| EOS-AX1360 | NB-598 Maleate | 155294-62-5 | C31H35NO5S2 | 565.74 | CCN(CC=CC#CC(C)(C)C)CC1=CC(=CC=C1)OCC2=CC(=CS2)C3=CSC=C3.C(=CC(=O)O)C(=O)O |
| EOS-AX1361 | NB-598 Maleate salt | 136719-26-1 | C31H35NO5S2 | 565.74 | CCN(CC1=CC(OCC2=CC(C3=CSC=C3)=CS2)=CC=C1)C/C=C/C#CC(C)(C)C.O=C(O)/C=C/C(O)=O |
| EOS-AX1362 | NBD-556 | 333353-44-9 | C17H24ClN3O2 | 337.84 | CC1(CC(CC(N1)(C)C)NC(=O)C(=O)NC2=CC=C(C=C2)Cl)C |
| EOS-AX1363 | NBD-557 | 333352-59-3 | C17H24BrN3O2 | 382.3 | CC1(CC(CC(N1)(C)C)NC(=O)C(=O)NC2=CC=C(C=C2)Br)C |
| EOS-AX1364 | N-Desethyl Sunitinib | 356068-97-8 | C20H23FN4O2 | 370.42 | CCNCCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C |
| EOS-AX1365 | Necrostatin 2 | 852391-19-6 | C13H12ClN3O2 | 277.71 | CN1C(=O)C(NC1=O)CC2=CNC3=C2C=CC=C3Cl |
| EOS-AX1366 | Nelfinavir Mesylate | 159989-65-8 | C33H49N3O7S2 | 663.89 | CC1=C(C=CC=C1O)C(=O)NC(CSC2=CC=CC=C2)C(CN3CC4CCCCC4CC3C(=O)NC(C)(C)C)O.CS(=O)(=O)O |
| EOS-AX1367 | Nepicastat | 173997-05-2 | C14H15F2N3S | 295.35 | C1CC2=C(C=C(C=C2CC1N3C(=CNC3=S)CN)F)F |
| EOS-AX1368 | Nesbuvir | 691852-58-1 | C22H23FN2O5S | 446.49 | CNC(=O)C1=C(OC2=CC(=C(C=C21)C3CC3)N(CCO)S(=O)(=O)C)C4=CC=C(C=C4)F |
| EOS-AX1369 | Nestoron | 7759-35-5 | C23H30O4 | 370.48 | CC(C1(OC(C)=O)C(CC2C1(C)CCC3C2CCC4=CC(CCC34)=O)=C)=O |
| EOS-AX1370 | NG 52 | 212779-48-1 | C16H19ClN6O | 346.81 | CC(C)N1C=NC2=C1N=C(N=C2NC3=CC(=CC=C3)Cl)NCCO |
| EOS-AX1371 | NG25 | 1315355-93-1 | C29H30F3N5O2 | 537.58 | CCN1CCN(CC1)CC2=C(C=C(C=C2)NC(=O)C3=CC(=C(C=C3)C)OC4=C5C=CNC5=NC=C4)C(F)(F)F |
| EOS-AX1372 | Nifuratel | 4936-47-4 | C10H11N3O5S | 285.28 | CSCC1CN(C(=O)O1)N=CC2=CC=C(O2)[N+](=O)[O-] |
| EOS-AX1373 | Nilotinib monohydrochloride monohydrate | 923288-90-8 | C28H25ClF3N7O2 | 583.99 | CC1=C(C=C(C=C1)C(=O)NC2=CC(=CC(=C2)N3C=C(N=C3)C)C(F)(F)F)NC4=NC=CC(=N4)C5=CN=CC=C5.O.Cl |
| EOS-AX1374 | NKP608 | 177707-12-9 | C31H24ClF6N3O2 | 619.98 | C1CN(C(CC1NC(=O)C2=CC=NC3=CC=CC=C23)CC4=CC=C(C=C4)Cl)C(=O)C5=CC(=CC(=C5)C(F)(F)F)C(F)(F)F |
| EOS-AX1375 | NNC 55-0396 | 357400-13-6 | C30H40Cl2FN3O2 | 564.56 | CC(C1C2=C(C=C(F)C=C2)CCC1(OC(C3CC3)=O)CCN(CCCC4=NC5=CC=CC=C5N4)C)C.Cl.Cl |
| EOS-AX1376 | Noopept | 157115-85-0 | C17H22N2O4 | 318.37 | CCOC(CNC(C1CCCN1C(CC2=CC=CC=C2)=O)=O)=O |
| EOS-AX1377 | Nordihydroguaiaretic acid | 500-38-9 | C18H22O4 | 302.36 | CC(C(CC1=CC(O)=C(O)C=C1)C)CC2=CC(O)=C(O)C=C2 |
| EOS-AX1378 | Nortadalafil | 171596-36-4 | C21H17N3O4 | 375.38 | O=C1N([H])C([H])([H])C(N2[C@@](C(C([H])=C3[H])=C([H])C4=C3OC([H])([H])O4)([H])C(N([H])C5=C([H])C([H])=C([H])C([H])=C65)=C6C([H])([H])[C@@]21[H])=O |
| EOS-AX1379 | NP118809 | 41332-24-5 | C32H32N2O | 460.61 | C1CN(CCN1C(C2=CC=CC=C2)C3=CC=CC=C3)C(=O)CC(C4=CC=CC=C4)C5=CC=CC=C5 |
| EOS-AX1380 | NPS-2143 hydrochloride | 324523-20-8 | C24H26Cl2N2O2 | 445.38 | CC(C)(CC1=CC2=CC=CC=C2C=C1)NCC(COC3=C(C(=CC=C3)Cl)C#N)O.Cl |
| EOS-AX1381 | NS309 | 18711-16-5 | C8H4Cl2N2O2 | 231.04 | O=C1N=C2C(Cl)=C(Cl)C=CC2=C1NO |
| EOS-AX1382 | Nuclear yellow | 74681-68-8 | C25H25N7O2S | 487.58 | CN1CCN(C2=CC3=C(N=C(C4=CC5=C(N=C(C6=CC=C(S(=O)(N)=O)C=C6)N5)C=C4)N3)C=C2)CC1 |
| EOS-AX1383 | Nucleozin | 341001-38-5 | C21H19ClN4O4 | 426.86 | CC1=C(C(=NO1)C2=CC=CC=C2)C(=O)N3CCN(CC3)C4=C(C=C(C=C4)[N+](=O)[O-])Cl |
| EOS-AX1384 | Nutlin-3a chiral | 675576-98-4 | C30H30Cl2N4O4 | 581.49 | CC(C)OC1=C(C=CC(=C1)OC)C2=NC(C(N2C(=O)N3CCNC(=O)C3)C4=CC=C(C=C4)Cl)C5=CC=C(C=C5)Cl |
| EOS-AX1385 | NVP-BAG956 | 853910-02-8 | C28H21N5 | 427.5 | CC1=NC2=CN=C3C=CC(C#CC4=CN=CC=C4)=CC3=C2N1C5=CC=C(C(C)(C#N)C)C=C5 |
| EOS-AX1386 | NVP-BGJ398 phosphate | 1310746-10-1 | C26H34Cl2N7O7P | 658.47 | COC1=C(Cl)C(NC(N(C)C2=CC(NC3=CC=C(N4CCN(CC)CC4)C=C3)=NC=N2)=O)=C(Cl)C(OC)=C1.OP(O)(O)=O |
| EOS-AX1387 | NVP-BKM120 Hydrochloride | 1312445-63-8 | C18H22ClF3N6O2 | 446.85 | C1COCCN1C2=NC(=NC(=C2)C3=CN=C(C=C3C(F)(F)F)N)N4CCOCC4.Cl |
| EOS-AX1388 | NVP-BSK805 | 1092499-93-8 | C27H28F2N6O | 490.55 | C1CNCCC1N2C=C(C=N2)C3=NC4=C(C=CC=C4N=C3)C5=CC(=C(C(=C5)F)CN6CCOCC6)F.Cl.Cl |
| EOS-AX1389 | NVP-LCQ195 | 902156-99-4 | C17H19Cl2N5O4S | 460.33 | CS(=O)(=O)N1CCC(CC1)NC(=O)C2=C(C=NN2)NC(=O)C3=C(C=CC=C3Cl)Cl |
| EOS-AX1390 | Octreotide acetate | 79517-01-4 | C51H70N10O12S2 | 1079.29 | |
| EOS-AX1391 | Oglemilast | 778576-62-8 | C20H13Cl2F2N3O5S | 516.3 | CS(=O)(=O)NC1=CC2=C(C=C1)OC3=C(C=CC(=C23)C(=O)NC4=C(C=NC=C4Cl)Cl)OC(F)F |
| EOS-AX1392 | Olcegepant | 204697-65-4 | C38H47Br2N9O5 | 869.66 | C1CN(CCC1N2CC3=CC=CC=C3NC2=O)C(=O)NC(CC4=CC(=C(C(=C4)Br)O)Br)C(=O)NC(CCCCN)C(=O)N5CCN(CC5)C6=CC=NC=C6 |
| EOS-AX1393 | Olmesartan | 144689-24-7 | C24H26N6O3 | 446.5 | CCCC1=NC(=C(N1CC2=CC=C(C=C2)C3=CC=CC=C3C4=NNN=N4)C(=O)O)C(C)(C)O |
| EOS-AX1394 | Olprinone | 106730-54-5 | C14H10N4O | 250.26 | CC1=C(C2=CN3C=CN=C3C=C2)C=C(C#N)C(N1)=O |
| EOS-AX1395 | Olprinone Hydrochloride | 119615-63-3 | C14H11ClN4O | 286.72 | CC1=C(C=C(C(=O)N1)C#N)C2=CN3C=CN=C3C=C2.Cl |
| EOS-AX1396 | ONO-AE3-208 | 402473-54-5 | C24H21FN2O3 | 404.43 | CC(C1=CC=C(C2=CC=CC=C21)F)C(=O)NC3=C(C=CC(=C3)C#N)CCCC(=O)O |
| EOS-AX1397 | Orteronel | 566939-85-3 | C18H17N3O2 | 307.35 | CNC(=O)C1=CC2=C(C=C1)C=C(C=C2)C3(CCN4C3=CN=C4)O |
| EOS-AX1398 | ortho-iodoHoechst 33258 | 158013-41-3 | C25H23IN6 | 534.39 | CN1CCN(CC1)C2=CC3=C(C=C2)N=C(N3)C4=CC5=C(C=C4)N=C(N5)C6=CC=CC=C6I |
| EOS-AX1399 | Oseltamivir | 196618-13-0 | C16H28N2O4 | 312.4 | CCC(CC)OC1C=C(CC(C1NC(=O)C)N)C(=O)OCC |
| EOS-AX1400 | Oseltamivir acid | 187227-45-8 | C14H24N2O4 | 284.35 | CCC(CC)OC1C=C(CC(C1NC(=O)C)N)C(=O)O |
| EOS-AX1401 | Otamixaban | 193153-04-7 | C25H26N4O4 | 446.53 | CC(C(CC1=CC=CC(=C1)C(=N)N)C(=O)OC)NC(=O)C2=CC=C(C=C2)C3=CC=[N+](C=C3)[O-] |
| EOS-AX1402 | Otenabant | 686344-29-6 | C25H25Cl2N7O | 510.42 | CCNC1(CCN(CC1)C2=NC=NC3=C2N=C(N3C4=CC=C(C=C4)Cl)C5=CC=CC=C5Cl)C(=O)N |
| EOS-AX1403 | OTX-015 | 202590-98-5 | C25H22ClN5O2S | 491.99 | CC1=C(SC2=C1C(=NC(C3=NN=C(N32)C)CC(=O)NC4=CC=C(C=C4)O)C5=CC=C(C=C5)Cl)C |
| EOS-AX1404 | p53 and MDM2 proteins-interaction-inhibitor chiral | 939981-37-0 | C40H49Cl2N5O4 | 734.75 | CCOC1=C(C=CC(=C1)C(C)(C)C)C2=NC(C(N2C(=O)N3CCN(CC3)CC(=O)N4CCOCC4)(C)C5=CC=C(C=C5)Cl)(C)C6=CC=C(C=C6)Cl |
| EOS-AX1405 | p53 and MDM2 proteins-interaction-inhibitor racemic | 939983-14-9 | C40H49Cl2N5O4 | 734.75 | CCOC1=C(C2=NC(C)(C3=CC=C(Cl)C=C3)C(C)(C4=CC=C(Cl)C=C4)N2C(N5CCN(CC(N6CCOCC6)=O)CC5)=O)C=CC(C(C)(C)C)=C1 |
| EOS-AX1406 | Pafuramidine | 186953-56-0 | C20H20N4O3 | 364.4 | CON=C(C1=CC=C(C=C1)C2=CC=C(O2)C3=CC=C(C=C3)C(=NOC)N)N |
| EOS-AX1407 | Palifosfamide | 31645-39-3 | C4H11Cl2N2O2P | 221.02 | C(CCl)NP(=O)(NCCCl)O |
| EOS-AX1408 | Palonosetron | 135729-61-2 | C19H24N2O | 296.41 | O=C1N(C2CN3CCC2CC3)CC4CCCC5=CC=CC1=C45 |
| EOS-AX1409 | Pamabrom | 606-04-2 | C11H18BrN5O3 | 348.2 | CC(C)(CO)N.CN1C2=C(C(=O)N(C1=O)C)NC(=N2)Br |
| EOS-AX1410 | PAP-1 | 870653-45-5 | C21H18O5 | 350.37 | C1=CC=C(C=C1)OCCCCOC2=C3C=CC(=O)OC3=CC4=C2C=CO4 |
| EOS-AX1411 | Paradol | 27113-22-0 | C17H26O3 | 278.39 | CCCCCCCC(=O)CCC1=CC(=C(C=C1)O)OC |
| EOS-AX1412 | para-iodoHoechst 33258 | 158013-43-5 | C25H23IN6 | 534.39 | CN1CCN(C2=CC3=C(N=C(C4=CC5=C(N=C(C6=CC=C(I)C=C6)N5)C=C4)N3)C=C2)CC1 |
| EOS-AX1413 | Paricalcitol | 131918-61-1 | C27H44O3 | 416.64 | CC(C=CC(C)C(C)(C)O)C1CCC2C1(CCCC2=CC=C3CC(CC(C3)O)O)C |
| EOS-AX1414 | PB-22 | 1400742-17-7 | C23H22N2O2 | 358.43 | |
| EOS-AX1415 | PD 123319 ditrifluoroacetate | 136676-91-0 | C35H34F6N4O7 | 736.66 | CC1=C(C=CC(=C1)CN2C=NC3=C2CC(N(C3)C(=O)C(C4=CC=CC=C4)C5=CC=CC=C5)C(=O)O)N(C)C.C(=O)(C(F)(F)F)O.C(=O)(C(F)(F)F)O |
| EOS-AX1416 | PDE-9 inhibitor | 1082743-70-1 | C22H27N5O2 | 393.49 | CC1CN(CC1C2=NC(=O)C3=CNN(C3=N2)C4CCOCC4)CC5=CC=CC=C5 |
| EOS-AX1417 | PDK1 inhibitor | 1001409-50-2 | C28H22F2N4O4 | 516.5 | C1=CC=C(C=C1)C(COC2=CC3=C(C=C2)NC(=O)N3)NC(=O)C4=CC=CN(C4=O)CC5=CC(=C(C=C5)F)F |
| EOS-AX1418 | Pemetrexed disodium hemipenta hydrate | 357166-30-4 | C20H23N5NaO7+ | 468.42 | C1=CC(=CC=C1CCC2=CNC3=C2C(=O)N=C(N3)N)C(=O)NC(CCC(=O)O)C(=O)O.O.[Na+] |
| EOS-AX1419 | Pentostatin | 53910-25-1 | C11H16N4O4 | 268.27 | C1C(C(OC1N2C=NC3=C2NC=NCC3O)CO)O |
| EOS-AX1420 | Peramivir | 330600-85-6 | C15H28N4O4 | 328.41 | CCC(CC)C(C1C(CC(C1O)C(=O)O)N=C(N)N)NC(=O)C |
| EOS-AX1421 | Perampanel | 380917-97-5 | C23H15N3O | 349.38 | |
| EOS-AX1422 | PF-03084014 | 865773-15-5 | C27H41F2N5O | 489.64 | CCCC(C(=O)NC1=CN(C=N1)C(C)(C)CNCC(C)(C)C)NC2CCC3=CC(=CC(=C3C2)F)F |
| EOS-AX1423 | PF-04217903 methanesulfonate | 956906-93-7 | C20H20N8O4S | 468.49 | CS(=O)(=O)O.C1=CC2=C(C=CC(=C2)CN3C4=NC(=CN=C4N=N3)C5=CN(N=C5)CCO)N=C1 |
| EOS-AX1424 | PF-04447943 | 1082744-20-4 | C20H25N7O2 | 395.46 | CC1CN(CC2=NC=CC=N2)CC1C3=NC(C4=CNN(C5CCOCC5)C4=N3)=O |
| EOS-AX1425 | PF-04457845 | 1020315-31-4 | C23H20F3N5O2 | 455.43 | C1CN(CCC1=CC2=CC(=CC=C2)OC3=NC=C(C=C3)C(F)(F)F)C(=O)NC4=NN=CC=C4 |
| EOS-AX1426 | PF-04971729 | 1210344-57-2 | C22H25ClO7 | 436.88 | CCOC1=CC=C(CC2=C(Cl)C=CC(C34C(O)C(O)C(O)C(CO4)(CO)O3)=C2)C=C1 |
| EOS-AX1427 | PF-3758309 | 898044-15-0 | C25H30N8OS | 490.62 | CC1=NC2=C(C(=N1)NC3=NNC4=C3CN(C4(C)C)C(=O)NC(CN(C)C)C5=CC=CC=C5)SC=C2 |
| EOS-AX1428 | PF-543 | 1415562-82-1 | C27H31NO4S | 465.6 | CC1=CC(=CC(=C1)OCC2=CC=C(C=C2)CN3CCCC3CO)CS(=O)(=O)C4=CC=CC=C4 |
| EOS-AX1429 | PF-543 Citrate | 1415562-83-2 | C33H39NO11S | 657.73 | CC1=CC(=CC(=C1)OCC2=CC=C(C=C2)CN3CCCC3CO)CS(=O)(=O)C4=CC=CC=C4.C(C(=O)O)C(CC(=O)O)(C(=O)O)O |
| EOS-AX1430 | PF-670462 | 950912-80-8 | C19H22Cl2FN5 | 410.32 | C1CCC(CC1)N2C=NC(=C2C3=NC(=NC=C3)N)C4=CC=C(C=C4)F.Cl.Cl |
| EOS-AX1431 | PF-8380 | 1144035-53-9 | C22H21Cl2N3O5 | 478.33 | ClC1=CC(COC(N2CCN(CCC(C(C=C3)=CC(O4)=C3NC4=O)=O)CC2)=O)=CC(Cl)=C1 |
| EOS-AX1432 | PHA-767491 | 845714-00-3 | C12H11N3O | 213.24 | C1CNC(=O)C2=C1NC(=C2)C3=CC=NC=C3 |
| EOS-AX1433 | Phenylpiracetam | 77472-70-9 | C12H14N2O2 | 218.25 | O=C1N(CC(N)=O)CC(C2=CC=CC=C2)C1 |
| EOS-AX1434 | Phloretin | 60-82-2 | C15H14O5 | 274.27 | O=C(C1=C(O)C=C(O)C=C1O)CCC2=CC=C(O)C=C2 |
| EOS-AX1435 | PI-103 Hydrochloride | 371935-79-4 | C19H17ClN4O3 | 384.82 | C1COCCN1C2=NC(=NC3=C2OC4=C3C=CC=N4)C5=CC(=CC=C5)O.Cl |
| EOS-AX1436 | PI3k-delta inhibitor 1 | 1332075-63-4 | C28H33FN6O2 | 504.6 | CC(C1CCN(CC2=NC3=C(N=C(C4=C(F)C=CC5=C4C=CN5)N=C3N6CCOCC6)C=C2)CC1)(O)C |
| EOS-AX1437 | Pitolisant | 362665-56-3 | C17H26ClNO | 295.85 | ClC(C=C1)=CC=C1CCCOCCCN2CCCCC2 |
| EOS-AX1438 | Pitolisant hydrochloride | 903576-44-3 | C17H27Cl2NO | 332.31 | C1CCN(CC1)CCCOCCCC2=CC=C(C=C2)Cl.Cl |
| EOS-AX1439 | Pitolisant oxalate | 362665-57-4 | C19H28ClNO5 | 385.88 | ClC1=CC=C(C=C1)CCCOCCCN2CCCCC2.OC(C(O)=O)=O |
| EOS-AX1440 | PJ34 | 344458-19-1 | C17H17N3O2 | 295.34 | CN(C)CC(=O)NC1=CC2=C(C=C1)NC(=O)C3=CC=CC=C32 |
| EOS-AX1441 | PND-1186 | 1061353-68-1 | C25H26F3N5O3 | 501.5 | CNC(C1=C(NC2=CC(NC3=CC=C(N4CCOCC4)C=C3OC)=NC=C2C(F)(F)F)C=CC=C1)=O |
| EOS-AX1442 | Podophyllotoxin | 518-28-5 | C22H22O8 | 414.41 | COC1=CC(C2C3C(C(O)C4=CC5=C(OCO5)C=C24)COC3=O)=CC(OC)=C1OC |
| EOS-AX1443 | Poloxin | 321688-88-4 | C18H19NO3 | 297.35 | CC1=CC=CC=C1C(=O)ON=C2C=C(C(=O)C=C2C)C(C)C |
| EOS-AX1444 | Pramipexole dihydrochloride | 104632-25-9 | C10H19Cl2N3S | 284.25 | CCCNC1CCC2=C(C1)SC(=N2)N.Cl.Cl |
| EOS-AX1445 | Pregabalin | 148553-50-8 | C8H17NO2 | 159.23 | |
| EOS-AX1446 | Preladenant | 377727-87-2 | C25H29N9O3 | 503.56 | NC(N1N=C(C2=CC=CO2)N=C13)=NC4=C3C=NN4CCN5CCN(C(C=C6)=CC=C6OCCOC)CC5 |
| EOS-AX1447 | PRT062607 Hydrochloride | 1370261-97-4 | C19H24ClN9O | 429.91 | NC(C1=C(NC2=CC(N3N=CC=N3)=CC=C2)N=C(N[C@H]4[C@H](N)CCCC4)N=C1)=O.Cl |
| EOS-AX1448 | PSI-6130 | 817204-33-4 | C10H14FN3O4 | 259.23 | CC1(C(C(OC1N2C=CC(=NC2=O)N)CO)O)F |
| EOS-AX1449 | PSI-7977 | 1190307-88-0 | C22H29FN3O9P | 529.45 | CC(C)OC(=O)C(C)NP(=O)(OCC1C(C(C(O1)N2C=CC(=O)NC2=O)(C)F)O)OC3=CC=CC=C3 |
| EOS-AX1450 | PU-H71 | 873436-91-0 | C18H21IN6O2S | 512.37 | CC(C)NCCCN1C2=C(C(=NC=N2)N)N=C1SC3=C(C=C4C(=C3)OCO4)I |
| EOS-AX1451 | Puromycin aminonucleoside | 58-60-6 | C12H18N6O3 | 294.31 | CN(C)C1=NC=NC2=C1N=CN2C3C(C(C(O3)CO)N)O |
| EOS-AX1452 | Pyridone 6 | 457081-03-7 | C18H16FN3O | 309.34 | CC(C)(C)C(N1)=NC2=C1C3=C(C4=C2C=CNC4=O)C=C(F)C=C3 |
| EOS-AX1453 | Pyridostatin | 1085412-37-8 | C31H32N8O5 | 596.64 | C1=CC=C2C(=C1)C(=CC(=N2)NC(=O)C3=CC(=CC(=N3)C(=O)NC4=NC5=CC=CC=C5C(=C4)OCCN)OCCN)OCCN |
| EOS-AX1454 | QL-IX-55 | 1223002-54-7 | C24H14F4N4O | 450.39 | O=C1C=CC2=CN=C3C=CC(C4=CN=C(N)C=C4)=CC3=C2N1C5=CC(C(F)(F)F)=C(F)C=C5 |
| EOS-AX1455 | Quetiapine | 111974-69-7 | C21H25N3O2S | 383.51 | C1CN(CCN1CCOCCO)C2=NC3=CC=CC=C3SC4=CC=CC=C42 |
| EOS-AX1456 | R-1479 | 478182-28-4 | C9H12N6O5 | 284.23 | C1=CN(C(=O)N=C1N)C2C(C(C(O2)(CO)N=[N+]=[N-])O)O |
| EOS-AX1457 | R1530 | 882531-87-5 | C18H14ClFN4O | 356.78 | CC1=C2C(=NC3=CC(=C(C=C3C(=N2)C4=CC=CC=C4Cl)F)OC)NN1 |
| EOS-AX1458 | R-7128 | 940908-79-2 | C18H26FN3O6 | 399.41 | CC(C)C(=O)OCC1C(C(C(O1)N2C=CC(=NC2=O)N)(C)F)OC(=O)C(C)C |
| EOS-AX1459 | rac-Rotigotine Hydrochloride | 102120-99-0 | C19H26ClNOS | 351.93 | CCCN(CCC1=CC=CS1)C2CCC3=C(C2)C=CC=C3O.Cl |
| EOS-AX1460 | Radezolid | 869884-78-6 | C22H23FN6O3 | 438.45 | CC(=O)NCC1CN(C(=O)O1)C2=CC(=C(C=C2)C3=CC=C(C=C3)CNCC4=NNN=C4)F |
| EOS-AX1461 | Regorafenib hydrochloride | 835621-07-3 | C21H16Cl2F4N4O3 | 519.28 | CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F.Cl |
| EOS-AX1462 | Regorafenib monohydrate | 1019206-88-2 | C21H17ClF4N4O4 | 500.83 | CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F.O |
